Endovascular stent-graft with fatigue-resistant lateral tube

Information

  • Patent Grant
  • 12193954
  • Patent Number
    12,193,954
  • Date Filed
    Wednesday, July 13, 2022
    2 years ago
  • Date Issued
    Tuesday, January 14, 2025
    9 days ago
Abstract
A stent-graft (20) comprises strut members (30) and a graft member (32), which is fixed to the strut members (30). The strut members (30) and the graft member (32) are arranged so as to define, when the stent-graft (20) is in a radially-expanded state: a main tube (40), which is shaped so as to define a main lumen (42); and a lateral tube (50), which (a) has (i) a distal end (52) and (ii) a proximal end (54) that is joined to a lateral wall (56) of the main tube (40) at a junction (60), (b) is shaped so as to define a lateral lumen (62) that is in fluid communication with the main lumen (42), and (c) defines a central longitudinal axis (64). The strut members (30) that define the lateral tube (50) are shaped so as to define two to four non-contiguous arcuate members (70), which (a) are centered around the central longitudinal axis (64), and (b) collectively subtend at least 150 degrees around the central longitudinal axis (64).
Description
FIELD OF THE APPLICATION

The present invention relates generally to implantable medical devices, and specifically to delivery tools and implantable stent-grafts.


BACKGROUND OF THE APPLICATION

Endovascular prostheses are sometimes used to treat aortic aneurysms. Such treatment includes implanting a stent or stent-graft within the diseased vessel to bypass the anomaly. An aneurysm is a sac formed by the dilation of the wall of the artery. Aneurysms may be congenital, but are usually caused by disease or, occasionally, by trauma. Aortic aneurysms which commonly form between the renal arteries and the iliac arteries are referred to as abdominal aortic aneurysms (“AAAs”). Other aneurysms occur in the aorta, such as thoracic aortic aneurysms (“TAAs”) and aortic uni-iliac (“AUI”) aneurysms. A TAA may occur downstream the aortic arch, i.e., in the descending aorta. Alternatively, a TAA may occur in the aortic arch itself, where the aorta branches to supply the brachiocephalic, left carotid and subclavian arteries, or may occur in the ascending aorta.


Endo-Vascular Aneurysm Repair (EVAR) has transformed the practice of treatment of aortic aneurysms from an open surgical approach to a much less invasive surgical approach. The first step of an endovascular intervention usually requires introducing a delivery system into the vasculature of a subject. If the crossing profile, i.e., the external diameter, of the delivery system is 24 Fr or lower (3 Fr=1 millimeter), a true percutaneous approach may be used, because vascular closure devices are available for proper closure of such puncture sites.


Blood vessels occasionally weaken or even rupture. For example, in the aortic artery, the vascular wall can weaken or tear, resulting in dangerous conditions such as aneurysm and dissection. Treatment of such conditions can be performed by implanting a prosthesis within the vascular system using minimally-invasive surgical procedures. An endoluminal prosthesis typically includes one or more stents affixed to graft material and is delivered to the treatment site by endovascular insertion. Once the endoluminal prosthesis is radially enlarged, it should remain in place indefinitely by self-attachment to the vessel wall, acting as a substitute vessel for the flow of blood or other fluids.


Aortic dissection is a tear or partial tear in the inner wall of the aorta, which causes blood to flow between the layers of the wall of the aorta, forcing the layers apart. Aortic dissections may be divided into two types in accordance with the Stanford classification: Type A dissections involve the ascending aorta and/or aortic arch, and possibly the descending aorta. Type B dissections involve the descending aorta or the arch (distal to right brachiocephalic artery origin), without involvement of the ascending aorta.


SUMMARY OF THE APPLICATION

In some embodiments of the present invention, a stent-graft comprises a plurality of structural strut members and a graft member, which are arranged so as to define a main tube and a lateral tube, when the stent-graft is in a radially-expanded state. The lateral tube has a proximal end that is joined to a lateral wall of the main tube. When the stent-graft is in the radially-expanded state, the structural strut members that the define lateral tube are shaped so as to define two to six, typically two to four, non-contiguous arcuate members, which (a) are centered around a central longitudinal axis of the lateral tube, and (b) collectively subtend at least 150 degrees around the central longitudinal axis. Typically, the arcuate members are arranged so as to provide respective circumferential gaps between circumferentially-adjacent ones of the arcuate members, when the stent-graft is in the radially-expanded state. This configuration of the structural stent members of the lateral tube tends to increase the fatigue resistance of the lateral tube during long-term implantation of the stent-graft in an aneurysmal artery.


For some applications, the structural strut members that define the lateral tube are shaped so as to define respective linking members for the arcuate members. The linking members link the arcuate members to the a junction at which the proximal end of the lateral tube is joined to the main tube, such as with one or more structural strut members that surround the proximal end of the lateral tube. For some of these applications, the linking members form respective angles with the respective arcuate members, which angles have an average of 30 to 90 degrees, when the stent-graft is in the radially-expanded state. In some configurations, the average angle is 85 to 90 degrees, e.g., 90 degrees, while for other applications, the average angle is 30 to 60 degrees, e.g., about 45 degrees.


For some applications, the arcuate members are disposed at a same axial position along the lateral tube, when the stent-graft is in the radially-expanded state. Typically, the arcuate members are disposed with 3 mm of a distal end of the structural strut members that define the lateral tube, when the stent-graft is in the radially-expanded state. For example, the arcuate members may be disposed at the distal end of the structural strut members that define the lateral tube, when the stent-graft is in the radially-expanded state. Typically, the arcuate members are disposed with 3 mm of a distal end of a portion of the graft member that defines the lateral tube, when the stent-graft is in the radially-expanded state. For example, the arcuate members may be disposed at the distal end of the portion of the graft member that defines the lateral tube, when the stent-graft is in the radially-expanded state.


There is therefore provided, in accordance with an inventive concept 1 of the present invention, apparatus comprising an endovascular stent-graft, which is configured to transition from a radially-compressed delivery state to a radially-expanded state, and which comprises:

    • a plurality of structural strut members; and
    • a graft member, which comprises one or more substantially blood-impervious flexible sheets, and which is fixed to the structural strut members,
    • wherein the structural strut members and the graft member are arranged so as to define, when the stent-graft is in the radially-expanded state:
      • a main tube, which is shaped so as to define a main lumen, and
      • a lateral tube, which (a) has (i) a distal end and (ii) a proximal end that is joined to a lateral wall of the main tube at a junction, (b) is shaped so as to define a lateral lumen that is in fluid communication with the main lumen, and (c) defines a central longitudinal axis, and
    • wherein, when the stent-graft is in the radially-expanded state, the structural strut members that define the lateral tube are shaped so as to define two to four non-contiguous arcuate members, which (a) are centered around the central longitudinal axis, and (b) collectively subtend at least 150 degrees around the central longitudinal axis.


      Inventive concept 2. The apparatus according to inventive concept 1, wherein the arcuate members collectively subtend at least 180 degrees around the central longitudinal axis, when the stent-graft is in the radially-expanded state.


      Inventive concept 3. The apparatus according to inventive concept 2, wherein the arcuate members collectively subtend at least 210 degrees around the central longitudinal axis, when the stent-graft is in the radially-expanded state.


      Inventive concept 4. The apparatus according to inventive concept 1, wherein at least one of the arcuate members alone subtends at least 60 degrees around the central longitudinal axis, when the stent-graft is in the radially-expanded state.


      Inventive concept 5. The apparatus according to inventive concept 1, wherein the arcuate members are disposed at a same axial position along the lateral tube, when the stent-graft is in the radially-expanded state.


      Inventive concept 6. The apparatus according to inventive concept 1, wherein at least two of the arcuate members are disposed at respective different axial positions along the lateral tube, when the stent-graft is in the radially-expanded state.


      Inventive concept 7. The apparatus according to inventive concept 1, wherein the arcuate members are disposed with 3 mm of a distal end of the structural strut members that define the lateral tube, when the stent-graft is in the radially-expanded state.


      Inventive concept 8. The apparatus according to inventive concept 7, wherein the arcuate members are disposed at the distal end of the structural strut members that define the lateral tube, when the stent-graft is in the radially-expanded state.


      Inventive concept 9. The apparatus according to inventive concept 1, wherein the arcuate members are disposed with 3 mm of a distal end of a portion of the graft member that defines the lateral tube, when the stent-graft is in the radially-expanded state.


      Inventive concept 10. The apparatus according to inventive concept 9, wherein the arcuate members are disposed at the distal end of the portion of the graft member that defines the lateral tube, when the stent-graft is in the radially-expanded state.


      Inventive concept 11. The apparatus according to inventive concept 1, wherein when the main tube is in a radially-expanded state thereof and the lateral tube is in a compressed delivery state thereof, the arcuate members define a portion of a generally tubular outer surface of the main tube.


      Inventive concept 12. The apparatus according to inventive concept 1, wherein the apparatus further comprises a branching stent-graft, which is configured to form a blood-tight seal with the lateral tube, when the stent-graft is in the radially-expanded state and the branching stent-graft is in a radially-expanded state.


      Inventive concept 13. The apparatus according to inventive concept 1, wherein a ratio of (a) an average circumference of the main tube and (b) an average circumference of the lateral tube is between 1:1 and 5:1, when the stent-graft is in the radially-expanded state.


      Inventive concept 14. The apparatus according to inventive concept 1, wherein a length of the lateral tube is between 10% and 30% of an average circumference of the lateral tube, when the stent-graft is in the radially-expanded state.


      Inventive concept 15. The apparatus according to inventive concept 1, wherein a circumference of the lateral tube at the proximal end of the lateral tube is between 5% and 30% greater than a circumference of the lateral tube at the distal end of the lateral tube, when the stent-graft is in the radially-expanded state.


      Inventive concept 16. The apparatus according to inventive concept 1, wherein an angle between the central longitudinal axis of the lateral tube and a central longitudinal axis of the main tube is greater than 80 degrees, when the stent-graft is in the radially-expanded state.


      Inventive concept 17. The apparatus according to inventive concept 1, wherein an angle between the central longitudinal axis of the lateral tube and a central longitudinal axis of the main tube is between 60 and 80 degrees, when the stent-graft is in the radially-expanded state.


      Inventive concept 18. The apparatus according to inventive concept 1, wherein an angle between the central longitudinal axis of the lateral tube and a central longitudinal axis of the main tube is between 30 and 60 degrees, when the stent-graft is in the radially-expanded state.


      Inventive concept 19. The apparatus according to inventive concept 1, wherein the main tube has proximal and distal ends, and wherein a circumference of the proximal end of the main tube is 3 to 10 cm, when the stent-graft is in the radially-expanded state.


      Inventive concept 20. The apparatus according to inventive concept 19, wherein a circumference of the distal end of the main tube is 6 to 12 cm, when the stent-graft is in the radially-expanded state.


      Inventive concept 21. The apparatus according to inventive concept 1, wherein a length of the main tube is 4 to 15 cm.


      Inventive concept 22. The apparatus according to inventive concept 1, wherein the one or more of the structural strut members comprise a flexible metal.


      Inventive concept 23. The apparatus according to inventive concept 22, wherein the metal comprises a superelastic alloy.


      Inventive concept 24. The apparatus according to inventive concept 23, wherein the alloy comprises Nitinol.


      Inventive concept 25. The apparatus according to inventive concept 1, wherein the one or more flexible sheets comprise polyethylene terephthalate.


      Inventive concept 26. The apparatus according to inventive concept 1, wherein the one or more flexible sheets comprise expanded polytetrafluoroethylene (PTFE).


      Inventive concept 27. The apparatus according to any one of inventive concepts 1-26, wherein the arcuate members are arranged so as to provide respective circumferential gaps between circumferentially-adjacent ones of the arcuate members, when the stent-graft is in the radially-expanded state.


      Inventive concept 28. The apparatus according to inventive concept 27, wherein the arcuate members collectively subtend no more than 350 degrees around the central longitudinal axis, when the stent-graft is in the radially-expanded state.


      Inventive concept 29. The apparatus according to inventive concept 28, wherein the arcuate members collectively subtend no more than 340 degrees around the central longitudinal axis, when the stent-graft is in the radially-expanded state.


      Inventive concept 30. The apparatus according to inventive concept 27, wherein each of the circumferential gaps measures at least 10 degrees, when the stent-graft is in the radially-expanded state.


      Inventive concept 31. The apparatus according to inventive concept 30, wherein each of the circumferential gaps measures at least 20 degrees, when the stent-graft is in the radially-expanded state.


      Inventive concept 32. The apparatus according to inventive concept 27, wherein the arcuate members are disposed at a same axial position along the lateral tube, when the stent-graft is in the radially-expanded state.


      Inventive concept 33. The apparatus according to inventive concept 32, wherein respective areas of the lateral tube, which (a) circumferentially correspond with the gaps and (b) extend from the axial position of the arcuate members along at least 50% of a distance between the axial position of the arcuate members and the junction, are free from the structural strut members, when the stent-graft is in the radially-expanded state.


      Inventive concept 34. The apparatus according to inventive concept 33, wherein the respective areas extend from the arcuate members along 60% of the distance.


      Inventive concept 35. The apparatus according to inventive concept 34, wherein the respective areas extend from the arcuate members along 100% of the distance.


      Inventive concept 36. The apparatus according to any one of inventive concepts 1-26, wherein the structural strut members that define the lateral tube are shaped so as to define respective linking members for the arcuate members, which linking members link the arcuate members to the junction.


      Inventive concept 37. The apparatus according to inventive concept 36, wherein, when the stent-graft is in the radially-expanded state, the lateral tube is free from the structural strut members, except for the arcuate members and the linking members, in an area that (a) extends entirely around the central longitudinal axis and (b) extends from the distal end of the lateral tube along at least 50% of a distance between the distal end of the lateral tube and the junction.


      Inventive concept 38. The apparatus according to inventive concept 37, wherein, when the stent-graft is in the radially-expanded state, the lateral tube is free from the structural strut members, except for the arcuate members, the linking members, and any of the structural strut members that surround the proximal end of the lateral tube at the junction.


      Inventive concept 39. The apparatus according to inventive concept 36, wherein an average length of the linking members equals at least 80% of a length of the lateral tube, when the stent-graft is in the radially-expanded state.


      Inventive concept 40. The apparatus according to inventive concept 36, wherein, when the stent-graft is in the radially-expanded state, respective points on the linking members and respective juncture points between the link members and the arcuate members define respective lines, which lines form respective angles with the respective arcuate members, which angles have an average of 30 to 90 degrees, and which points on the linking members are at 30% of a distance between the axial position of the arcuate members and the junction.


      Inventive concept 41. The apparatus according to inventive concept 40, wherein an average length of the linking members equals at least 80% of a length of the lateral tube, when the stent-graft is in the radially-expanded state.


      Inventive concept 42. The apparatus according to inventive concept 40, wherein the average is 85 to 90 degrees.


      Inventive concept 43. The apparatus according to inventive concept 42, wherein the average is 90 degrees.


      Inventive concept 44. The apparatus according to inventive concept 40, wherein the average is 30 to 60 degrees.


      Inventive concept 45. The apparatus according to inventive concept 40, wherein the linking members form respective angles with the respective arcuate members, which angles have an average of 30 to 90 degrees, when the stent-graft is in the radially-expanded state.


      Inventive concept 46. The apparatus according to inventive concept 45, wherein the average is 85 to 90 degrees.


      Inventive concept 47. The apparatus according to inventive concept 46, wherein the average is 90 degrees.


      Inventive concept 48. The apparatus according to inventive concept 45, wherein the average is 30 to 60 degrees.


      Inventive concept 49. The apparatus according to inventive concept 36, wherein each of the linking members is connected to its respective arcuate member at a juncture point at a location along the arcuate member that is within a number of degrees of a circumferential center of the arcuate member around the central circumferential axis, which number of degrees is equal to 40% of a total number of degrees of the arcuate member.


      Inventive concept 50. The apparatus according to inventive concept 49, wherein the location along the arcuate member is at the circumferential center of the arcuate member.


      Inventive concept 51. The apparatus according to inventive concept 36, wherein, when the stent-graft is in the radially-expanded state, one or more of the structural strut members (a) completely surround the proximal end of the lateral tube at the junction and (b) are connected to the linking members.


      Inventive concept 52. The apparatus according to any one of inventive concepts 1-26, wherein one or more of the structural strut members completely surround the proximal end of the lateral tube at the junction, when the stent-graft is in the radially-expanded state.


      Inventive concept 53. The apparatus according to inventive concept 52,
    • wherein the structural strut members that define the main tube are shaped so as a plurality of circumferential stent springs, each of which is shaped so as to define a plurality of stent cells, and
    • wherein one of the stent cells of one of the circumferential stent springs is defined by the one or more of the structural strut members that completely surround the proximal end of the lateral tube at the junction, when the stent-graft is in the radially-expanded state.


      Inventive concept 54. The apparatus according to inventive concept 53, wherein the stent cells of the one of the circumferential stent springs are diamond-shaped, when the stent-graft is in the radially-expanded state.


      Inventive concept 55. The apparatus according to inventive concept 54, wherein the diamond-shaped stent cells have respective, different dimensions, when the stent-graft is in the radially-expanded state.


      Inventive concept 56. The apparatus according to inventive concept 55, wherein a largest one of the diamond-shaped stent cells is at least 100% greater in surface area than a smallest one of the diamond-shaped stent cells, which largest one of the diamond-shaped stent cells is the one of the stent cells that is defined by the one or more of the structural strut members that completely surround the proximal end of the lateral tube at the junction, when the stent-graft is in the radially-expanded state.


      Inventive concept 57. The apparatus according to inventive concept 56,


Inventive concept wherein the lateral tube is a first lateral tube, the distal and proximal ends are first distal and proximal ends, the junction is a first junction, the lateral lumen is a first lateral lumen, the central longitudinal axis is a first central longitudinal axis, and the arcuate members are first arcuate members,

    • wherein the structural strut members and the graft member are arranged so as to define, when the stent-graft is in the radially-expanded state, a second lateral tube, which (a) has (i) a second distal end and (ii) a second proximal end that is joined to the lateral wall of the main tube at a second junction, (b) is shaped so as to define a second lateral lumen that is in fluid communication with the main lumen, and (c) defines a second central longitudinal axis,
    • wherein, when the stent-graft is in the radially-expanded state, the structural strut members that define the second lateral tube are shaped so as to define two to four non-contiguous second arcuate members, which (a) are centered around the second central longitudinal axis, and (b) collectively subtend at least 150 degrees around the second central longitudinal axis, and
    • wherein the smallest one of the diamond-shaped stent cells completely surrounds the second proximal end of the second lateral tube at the second junction, when the stent-graft is in the radially-expanded state.


There is further provided, in accordance with an inventive concept 58 of the present invention, a method for treating a subject, comprising:

    • transvascularly introducing an endovascular stent-graft into a blood vessel of the subject while the stent-graft is in a radially-compressed delivery state, which stent-graft comprises (a) a plurality of structural strut members, and (b) a graft member, which comprises one or more substantially blood-impervious flexible sheets, and which is fixed to the structural strut members; and
    • transitioning the stent-graft to a radially-expanded state, in which:
      • the structural strut members and the graft member are arranged so as to define (x) a main tube, which is shaped so as to define a main lumen, and (y) a lateral tube, which (a) has (i) a distal end and (ii) a proximal end that is joined to a lateral wall of the main tube at a junction, (b) is shaped so as to define a lateral lumen that is in fluid communication with the main lumen, and (c) defines a central longitudinal axis, and
      • the structural strut members that define the lateral tube are shaped so as to define two to four non-contiguous arcuate members, which (a) are centered around the central longitudinal axis, and (b) collectively subtend at least 150 degrees around the central longitudinal axis.


        Inventive concept 59. The method according to inventive concept 58, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which the arcuate members collectively subtend at least 180 degrees around the central longitudinal axis.


        Inventive concept 60. The method according to inventive concept 59, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which the arcuate members collectively subtend at least 210 degrees around the central longitudinal axis.


        Inventive concept 61. The method according to inventive concept 58, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which at least one of the arcuate members alone subtends at least 60 degrees around the central longitudinal axis.


        Inventive concept 62. The method according to inventive concept 58, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which the arcuate members are disposed at a same axial position along the lateral tube.


        Inventive concept 63. The method according to inventive concept 58, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which at least two of the arcuate members are disposed at respective different axial positions along the lateral tube.


        Inventive concept 64. The method according to inventive concept 58, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which the arcuate members are disposed with 3 mm of a distal end of the structural strut members that define the lateral tube.


        Inventive concept 65. The method according to inventive concept 64, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which the arcuate members are disposed at the distal end of the structural strut members that define the lateral tube.


        Inventive concept 66. The method according to inventive concept 58, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which the arcuate members are disposed with 3 mm of a distal end of a portion of the graft member that defines the lateral tube.


        Inventive concept 67. The method according to inventive concept 66, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which the arcuate members are disposed at the distal end of the portion of the graft member that defines the lateral tube.


        Inventive concept 68. The method according to inventive concept 58, wherein transitioning comprises:


transitioning the main tube to a radially-expanded state thereof while the lateral tube remains in a compressed delivery state thereof, in which the arcuate members define a portion of a generally tubular outer surface of the main tube; and


thereafter, transitioning the lateral tube to a radially-expanded state thereof, such that the stent-graft is in the radially-expanded state thereof.


Inventive concept 69. The method according to inventive concept 58, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which a ratio of (a) an average circumference of the main tube and (b) an average circumference of the lateral tube is between 1:1 and 5:1.


Inventive concept 70. The method according to inventive concept 58, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which a length of the lateral tube is between 10% and 30% of an average circumference of the lateral tube.


Inventive concept 71. The method according to inventive concept 58, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which a circumference of the lateral tube at the proximal end of the lateral tube is between 5% and 30% greater than a circumference of the lateral tube at the distal end of the lateral tube.


Inventive concept 72. The method according to inventive concept 58, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which an angle between the central longitudinal axis of the lateral tube and a central longitudinal axis of the main tube is greater than 80 degrees.


Inventive concept 73. The method according to inventive concept 58, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which an angle between the central longitudinal axis of the lateral tube and a central longitudinal axis of the main tube is between 60 and 80 degrees.


Inventive concept 74. The method according to inventive concept 58, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which an angle between the central longitudinal axis of the lateral tube and a central longitudinal axis of the main tube is between 30 and 60 degrees.


Inventive concept 75. The method according to inventive concept 58, wherein the main tube has proximal and distal ends, and wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which a circumference of the proximal end of the main tube is 3 to 10 cm.


Inventive concept 76. The method according to inventive concept 75, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which a circumference of the distal end of the main tube is 6 to 12 cm.


Inventive concept 77. The method according to inventive concept 58,

    • wherein transvascularly introducing the stent-graft comprises transvascularly introducing the stent-graft while the stent-graft is restrained in the radially-compressed delivery state within an elongate delivery tube, and
    • wherein transitioning the stent-graft to a radially-expanded state comprises releasing the stent-graft from the elongate delivery tube.


      Inventive concept 78. The method according to inventive concept 77, wherein a ratio of (a) an average circumference of the main tube when in a radially-expanded state thereof to (b) an inner circumference of the delivery tube is at least 5.


      Inventive concept 79. The method according to inventive concept 58, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which the arcuate members are arranged so as to provide respective circumferential gaps between circumferentially-adjacent ones of the arcuate members.


      Inventive concept 80. The method according to inventive concept 79, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which the arcuate members collectively subtend no more than 350 degrees around the central longitudinal axis.


      Inventive concept 81. The method according to inventive concept 80, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which the arcuate members collectively subtend no more than 340 degrees around the central longitudinal axis.


      Inventive concept 82. The method according to inventive concept 79, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which each of the circumferential gaps measures at least 10 degrees.


      Inventive concept 83. The method according to inventive concept 82, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which each of the circumferential gaps measures at least 20 degrees.


      Inventive concept 84. The method according to inventive concept 79, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which the arcuate members are disposed at a same axial position along the lateral tube.


      Inventive concept 85. The method according to inventive concept 84, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which respective areas of the lateral tube, which (a) circumferentially correspond with the gaps and (b) extend from the axial position of the arcuate members along at least 50% of a distance between the axial position of the arcuate members and the junction, are free from the structural strut members.


      Inventive concept 86. The method according to inventive concept 85, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which the respective areas extend from the arcuate members along 60% of the distance.


      Inventive concept 87. The method according to inventive concept 86, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which the respective areas extend from the arcuate members along 100% of the distance.


      Inventive concept 88. The method according to inventive concept 58, wherein the structural strut members that define the lateral tube are shaped so as to define respective linking members for the arcuate members, which linking members link the arcuate members to the junction.


      Inventive concept 89. The method according to inventive concept 88, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which the lateral tube is free from the structural strut members, except for the arcuate members and the linking members, in an area that (a) extends entirely around the central longitudinal axis and (b) extends from the distal end of the lateral tube along at least 50% of a distance between the distal end of the lateral tube and the junction.


      Inventive concept 90. The method according to inventive concept 89, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which the lateral tube is free from the structural strut members, except for the arcuate members, the linking members, and any of the structural strut members that surround the proximal end of the lateral tube at the junction.


      Inventive concept 91. The method according to inventive concept 88, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which an average length of the linking members equals at least 80% of a length of the lateral tube.


      Inventive concept 92. The method according to inventive concept 88, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which respective points on the linking members and respective juncture points between the link members and the arcuate members define respective lines, which lines form respective angles with the respective arcuate members, which angles have an average of 30 to 90 degrees, and which points on the linking members are at 30% of a distance between the axial position of the arcuate members and the junction.


      Inventive concept 93. The method according to inventive concept 92, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which an average length of the linking members equals at least 80% of a length of the lateral tube.


      Inventive concept 94. The method according to inventive concept 92, wherein the average is 85 to 90 degrees.


      Inventive concept 95. The method according to inventive concept 94, wherein the average is 90 degrees.


      Inventive concept 96. The method according to inventive concept 92, wherein the average is 30 to 60 degrees.


      Inventive concept 97. The method according to inventive concept 92, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which the linking members form respective angles with the respective arcuate members, which angles have an average of 30 to 90 degrees.


      Inventive concept 98. The method according to inventive concept 97, wherein the average is 85 to 90 degrees.


      Inventive concept 99. The method according to inventive concept 98, wherein the average is 90 degrees.


      Inventive concept 100. The method according to inventive concept 97, wherein the average is 30 to 60 degrees.


      Inventive concept 101. The method according to inventive concept 88, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which each of the linking members is connected to its respective arcuate member at a juncture point at a location along the arcuate member that is within a number of degrees of a circumferential center of the arcuate member around the central circumferential axis, which number of degrees is equal to 40% of a total number of degrees of the arcuate member.


      Inventive concept 102. The method according to inventive concept 101, wherein the location along the arcuate member is at the circumferential center of the arcuate member.


      Inventive concept 103. The method according to inventive concept 88, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which one or more of the structural strut members (a) completely surround the proximal end of the lateral tube at the junction and (b) are connected to the linking members.


      Inventive concept 104. The method according to inventive concept 58, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which one or more of the structural strut members completely surround the proximal end of the lateral tube at the junction.


      Inventive concept 105. The method according to inventive concept 104, wherein the structural strut members that define the main tube are shaped so as a plurality of circumferential stent springs, each of which is shaped so as to define a plurality of stent cells, and wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which one of the stent cells of one of the circumferential stent springs is defined by the one or more of the structural strut members that completely surround the proximal end of the lateral tube at the junction.


      Inventive concept 106. The method according to inventive concept 105, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which the stent cells of the one of the circumferential stent springs are diamond-shaped.


      Inventive concept 107. The method according to inventive concept 106, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which the diamond-shaped stent cells have respective, different dimensions.


      Inventive concept 108. The method according to inventive concept 107, wherein transitioning comprises transitioning the stent-graft to the radially-expanded state in which a largest one of the diamond-shaped stent cells is at least 100% greater in surface area than a smallest one of the diamond-shaped stent cells, which largest one of the diamond-shaped stent cells is the one of the stent cells that is defined by the one or more of the structural strut members that completely surround the proximal end of the lateral tube at the junction.


      109. The method according to inventive concept 108,
    • wherein the lateral tube is a first lateral tube, the distal and proximal ends are first distal and proximal ends, the junction is a first junction, the lateral lumen is a first lateral lumen, the central longitudinal axis is a first central longitudinal axis, and the arcuate members are first arcuate members,
    • wherein transitioning comprises transitioning the stent-graft to the radially-expanded state, in which:
      • the structural strut members and the graft member are arranged so as to define a second lateral tube, which (a) has (i) a second distal end and (ii) a second proximal end that is joined to the lateral wall of the main tube at a second junction, (b) is shaped so as to define a second lateral lumen that is in fluid communication with the main lumen, and (c) defines a second central longitudinal axis, and
      • the structural strut members that define the second lateral tube are shaped so as to define two to four non-contiguous second arcuate members, which (a) are centered around the second central longitudinal axis, and (b) collectively subtend at least 150 degrees around the second central longitudinal axis, and
      • wherein the smallest one of the diamond-shaped stent cells completely surrounds the second proximal end of the second lateral tube at the second junction, when the stent-graft is in the radially-expanded state.


        Inventive concept 110. The method according to inventive concept 58, wherein transvascularly introducing the stent-graft into the blood vessel comprises transvascularly introducing the stent-graft into an aorta of the subject.


        Inventive concept 111. The method according to inventive concept 110, wherein transvascularly introducing the stent-graft into the aorta comprises transvascularly introducing the stent-graft into an aneurysmal aorta.


        Inventive concept 112. The method according to inventive concept 58, further comprising:
    • transvascularly introducing a branching stent-graft through a portion of the main tube and into a branching blood vessel while the branching stent-graft is in a radially-compressed delivery state thereof; and
    • transitioning the branching stent-graft to a radially-expanded state thereof, in which the branching stent-graft forms a blood-tight seal with the lateral tube.


      Inventive concept 113. The method according to inventive concept 112,
    • wherein transvascularly introducing the stent-graft into the blood vessel comprises transvascularly introducing the stent-graft into an aneurysmal aorta of the subject, and
    • wherein transvascularly introducing the branching stent-graft into the branching blood vessel comprises transvascularly introducing the branching stent-graft into a visceral artery of the subject.


      Inventive concept 114. The method according to inventive concept 113, wherein the visceral artery is a renal artery.


      Inventive concept 115. The method according to inventive concept 113, wherein the visceral artery is a superior mesenteric artery (SMA).


      Inventive concept 116. The method according to inventive concept 113, wherein the visceral artery is a celiac artery.


The present invention will be more fully understood from the following detailed description of embodiments thereof, taken together with the drawings, in which:





BRIEF DESCRIPTION OF THE DRAWINGS


FIGS. 1A-B are schematic illustrations of a portion of an endovascular stent-graft, in accordance with an application of the present invention;



FIG. 2A is a schematic illustration of another configuration of the stent-graft of FIGS. 1A-B, in accordance with an application of the present invention;



FIG. 2B, which is a schematic illustration of yet another configuration of stent-graft 20, in accordance with an application of the present invention;



FIGS. 3A-B are schematic illustrations of a portion of another endovascular stent-graft, in accordance with an application of the present invention;



FIGS. 4A-B are schematic illustrations of a portion of yet another endovascular stent-graft, in accordance with an application of the present invention;



FIGS. 5A and 5B, which are schematic illustrations of portions of the stent-grafts of FIGS. 1A-B and 4A-B, respectively, in accordance with respective applications of the present invention; and



FIG. 6A-B are schematic illustrations of exemplary deployments of the stent-graft of FIGS. 3A-B, in accordance with respective applications of the present invention.





DETAILED DESCRIPTION OF APPLICATIONS


FIGS. 1A and 1B are schematic illustrations of a portion of an endovascular stent-graft 20, in accordance with an application of the present invention. Stent-graft 20 is configured to transition from a radially-compressed delivery state (not shown) to a radially-expanded state (as shown in FIG. 1A). Stent-graft 20 comprises a plurality of structural strut members 30 and a graft member 32, which is fixed to structural strut members 30.


Structural strut members 30 and graft member 32 are arranged so as to define, when stent-graft 20 is in the radially-expanded state:

    • a main tube 40, which is shaped so as to define a main lumen 42, and
    • a lateral tube 50, which (a) has (i) a distal end 52 and (ii) a proximal end 54 that is joined to a lateral wall 56 of main tube 40 at a junction 60 (junction 60 is flush with the external surface of main tube 40), (b) is shaped so as to define a lateral lumen 62 that is in fluid communication with main lumen 42, and (c) defines a central longitudinal axis 64.


When stent-graft 20 is in the radially-expanded state, as shown in FIG. 1A, structural strut members 30 that define lateral tube 50 are shaped so as to define two to six, typically two to four, non-contiguous arcuate members 70, which (a) are centered around central longitudinal axis 64, and (b) collectively subtend at least 150 degrees around central longitudinal axis 64, such as at least 180 degrees, e.g., at least 210 degrees around central longitudinal axis 64, such as at least 300 degrees, e.g., at least 340 degrees. (It is to be understood that not all of structural strut members 30 that define lateral tube 50 necessarily are shaped so as to define arcuate members 70; typically, only a portion of structural strut members 30 that define lateral tube 50 are shaped so as to define arcuate members 70.) For example, in the configuration shown in FIGS. 1A and 1B, structural strut members 30 that define lateral tube 50 are shaped so as to define exactly two non-contiguous arcuate members 70, each of which subtends an angle α (alpha) around central longitudinal axis 64, such that they collectively subtend an angle equal to 2α (twice alpha). For some applications, at least one of arcuate members 70 alone subtends at least 60 degrees around central longitudinal axis 64 when stent-graft 20 is in the radially-expanded state. For example, in the configuration shown in FIGS. 1A and 1B, angle α (alpha) is greater than 60 degrees, such that each of the arcuate members, taken separately, subtends at least 60 degrees around central longitudinal axis 64.


For some applications, stent-graft 20 is self-expanding, in which case the radially-expanded state is a relaxed state of the stent-graft. For these applications, lateral tube 50 is typically self-protruding from main tube 40. As used in the present application, including in the claims, a “central longitudinal axis” of an elongate structure is the set of all centroids of transverse cross-sectional sections of the structure along the structure. Thus the cross-sectional sections are locally perpendicular to the central longitudinal axis, which runs along the structure. (If the structure is circular in cross-section, the centroids correspond with the centers of the circular cross-sectional sections.)


Typically, structural strut members 30 comprise a metal, such as a flexible metal, an elastic metal, stainless steel, or a superelastic alloy (such as Nitinol). Graft member 32 comprises one or more biologically-compatible substantially blood-impervious flexible sheets 34, and is attached (such as by stitching) to at least a portion of structural strut members 30, on either side of the surfaces defined by the support element, so as to define lumens 42 and 62. The flexible sheets may comprise, for example, a polymeric material (e.g., a polyester, or polytetrafluoroethylene), a textile material (e.g., polyethylene terephthalate (PET), or expanded polytetrafluoroethylene (ePTFE)), natural tissue (e.g., saphenous vein or collagen), or a combination thereof.


Typically, arcuate members 70 are disposed with 3 mm of a distal end of structural strut members 30 that define lateral tube 50, when stent-graft 20 is in the radially-expanded state. For example, arcuate members 70 may be disposed at the distal end of structural strut members 30 that define lateral tube 50, when stent-graft 20 is in the radially-expanded state, such as shown in FIG. 1A. Typically, arcuate members 70 are disposed with 3 mm of a distal end of a portion of graft member 32 that defines lateral tube 50, when stent-graft 20 is in the radially-expanded state. For example, arcuate members 70 may be disposed at the distal end of the portion of graft member 32 that defines lateral tube 50, when stent-graft 20 is in the radially-expanded state, such as shown in FIG. 1A.



FIG. 1B shows stent-graft 20 when main tube 40 is in a radially-expanded state thereof and lateral tube 50 is in a compressed delivery state thereof. For some applications, such as shown in FIG. 1B, when main tube 40 is in a radially-expanded state thereof and lateral tube 50 is in a compressed delivery state thereof, arcuate members 70 define a portion of a generally tubular outer surface of main tube 40.


Typically, arcuate members 70 are arranged so as to provide respective circumferential gaps 80 between circumferentially-adjacent ones of arcuate members 70, when stent-graft 20 is in the radially-expanded state. For example, in the configuration shown in FIG. 1A, arcuate members 70 are arranged so as to provide exactly two circumferential gaps 80. For some applications, arcuate members 70 collectively subtend no more than 350 degrees around central longitudinal axis 64, such as no more than 340 degrees, when stent-graft 20 is in the radially-expanded state. For example, as shown in FIG. 1A, in the configuration shown in FIGS. 1A and 1B, structural strut members 30 that define lateral tube 50 are shaped so as to define exactly two non-contiguous arcuate members 70, each of which subtends an angle α (alpha) around central longitudinal axis 64, such that they collectively subtend an angle equal to 2α (twice alpha), which is no more than 350 degrees. For some applications, each of the circumferential gaps measures at least 10 degrees, such as at least 20 degrees, when stent-graft 20 is in the radially-expanded state.


For some applications, such as shown in FIG. 1A (and in FIGS. 2A, 3A, 4A, and 5A-B, described hereinbelow), arcuate members 70 are disposed at a same axial position along lateral tube 50, when stent-graft 20 is in the radially-expanded state. For some of these applications, such as shown in FIG. 1A, respective areas 82 of lateral tube 50, which (a) circumferentially correspond with the gaps and (b) extend from the axial position of arcuate members 70 along at least 50%, such as at least 60%, e.g., 100% (as shown in FIG. 1A), of a distance D between the axial position of arcuate members 70 and junction 60, are free from structural strut members 30, when stent-graft 20 is in the radially-expanded state.


For some applications, one or more of structural strut members 30 (these one or more structural strut members are labeled 86 in the figures) surround proximal end 54 of lateral tube 50 at junction 60. For some applications, one or more of structural strut members 30 (these one or more structural strut members are labeled 86 in the figures) surround proximal end 54, such as completely (i.e., around 360 degrees) surround proximal end 54, when stent-graft 20 is in the radially-expanded state.


For some applications, structural strut members 30 that define lateral tube 50 are shaped so as to define respective linking members 84 for arcuate members 70. Linking members 84 link arcuate members 70 to junction 60, such as with the one or more structural strut members 86 that surround proximal end 54, for applications in which these surrounding strut members are provided. (It is to be understood that not all of structural strut members 30 that define lateral tube 50 necessarily are shaped so as to define linking members 84; typically, only a portion of structural strut members 30 that define lateral tube 50 are shaped so as to define linking members 84.) For some applications, linking members 84 form respective angles β (beta) with the respective arcuate members 70, which angles have an average of 30 to 90 degrees, such as 85 to 90 degrees, e.g., 90 degrees, when stent-graft 20 is in the radially-expanded state. For some applications, an average length of linking members 84 equals at least 80% of a length of lateral tube 50.


For some applications, such as shown in FIG. 1A (and in FIGS. 2A-B, 3A, 4A, and 5A-B, described hereinbelow), when stent-graft 20 is in the radially-expanded state, lateral tube 50 is free from structural strut members 30, except for arcuate members 70 and linking members 84, in an area that (a) extends entirely around central longitudinal axis 64 and (b) extends from distal end 52 of lateral tube 50 along at least 50% of a distance between distal end 52 of lateral tube 50 and junction 60. For some of these applications, such as also shown in FIG. 1A (and in FIGS. 2A-B, 3A, 4A, and 5A-B, described hereinbelow), when stent-graft 20 is in the radially-expanded state, lateral tube 50 is free from structural strut members 30, except for arcuate members 70, linking members 84, and any of structural strut members 30 that surround proximal end 54 of lateral tube 50 at junction 60.


For some applications, structural strut members 30 that define main tube 40 are arranged as a plurality of circumferential stent springs 88, each of which is shaped so as to define a plurality of stent cells 90. (It is to be understood that not all of structural strut members 30 that define main tube 40 necessarily are shaped so as to define stent springs 88; for some applications, only a portion of structural strut members 30 that define main tube 40 are shaped so as to define stent springs 88.) Typically, axially-adjacent ones of the stent springs are not in contact with one another, when stent-graft 20 is in the radially-expanded state. For some applications, stent cells 90 are diamond-shaped, when stent-graft 20 is in the radially-expanded state. For some applications, the diamond-shaped stent cells 90 have respective, different dimensions, when stent-graft 20 is in the radially-expanded state.


Typically, one of stent cells 90 of one of stent springs 88 is defined by the one or more of structural strut members 30 that completely surround proximal end 54 of lateral tube 50 at junction 60, when stent-graft 20 is in the radially-expanded state.


For some applications, a ratio of (a) an average circumference of main tube 40 and (b) an average circumference of lateral tube 50 is between 1:1 and 5:1, when stent-graft 20 is in the radially-expanded state. For some applications, a length of lateral tube 50 is between 10% and 30% of an average circumference of lateral tube 50, when stent-graft 20 is in the radially-expanded state. For some applications, a circumference of lateral tube 50 at proximal end 54 of lateral tube 50 is between 5% and 30% greater than a circumference of lateral tube 50 at distal end 52 of lateral tube 50, when stent-graft 20 is in the radially-expanded state. For some applications, a length of main tube 40 is 4 to 15 cm.


For some applications, an angle between central longitudinal axis 64 of lateral tube 50 and a central longitudinal axis of main tube 40 is greater than 80 degrees, when stent-graft 20 is in the radially-expanded state. For some applications, an angle between central longitudinal axis 64 of lateral tube 50 and a longitudinal axis of main tube 40 is between 60 and 80 degrees, when stent-graft 20 is in the radially-expanded state. For some applications, an angle between central longitudinal axis 64 of lateral tube 50 and a longitudinal axis of main tube 40 is between 30 and 60 degrees, when stent-graft 20 is in the radially-expanded state.


For some applications, stent-graft 20 comprises two or more (e.g., exactly two or exactly three) lateral tubes 50, such as described hereinbelow with reference to FIGS. 3A-B, mutatis mutandis.


Reference is now made to FIG. 2A, which is a schematic illustration of another configuration of stent-graft 20, in accordance with an application of the present invention. In this configuration, structural strut members 30 that define lateral tube 50 are shaped so as to define exactly four non-contiguous arcuate members 70, each of which subtends an angle α (alpha) around central longitudinal axis 64, such that they collectively subtend an angle equal to 4α (four times alpha). Arcuate members 70 are arranged so as to provide exactly four circumferential gaps 80.


Reference is now made to FIG. 2B, which is a schematic illustration of yet another configuration of stent-graft 20, in accordance with an application of the present invention. In this configuration, at least two of arcuate members 70 are disposed at respective different axial positions along lateral tube 50, when stent-graft 20 is in the radially-expanded state.


Reference is now made to FIGS. 3A and 3B, which are schematic illustrations of a portion of an endovascular stent-graft 120, in accordance with an application of the present invention. Other than as described below, stent-graft 120 is identical to stent-graft 20, described hereinabove with reference to FIGS. 1A-B and 2A-B, and may implement any of the features of stent-graft 20.


As mentioned above with reference to FIGS. 1A-B, for some applications, structural strut members 30 that define main tube 40 are arranged as a plurality of circumferential stent springs 88, each of which is shaped so as to define a plurality of stent cells 90. Typically, axially-adjacent ones of the stent springs are not in contact with one another, when stent-graft 20 is in the radially-expanded state. Typically, one of stent cells 90 of one of stent springs 88 is defined by the one or more of structural strut members 30 that completely surround proximal end 54 of lateral tube 50 at junction 60, when stent-graft 20 is in the radially-expanded state. For some applications, stent cells 90 are diamond-shaped, when stent-graft 20 is in the radially-expanded state. For some applications, the diamond-shaped stent cells 90 have respective, different dimensions, when stent-graft 20 is in the radially-expanded state.


In the configuration shown in FIGS. 3A-B, a largest one of stent cells 90 (labeled 90A) (e.g., the diamond-shaped stent cells) is at least 100% greater in surface area than a smallest one of stent cells 90 (labeled 90B) (e.g., the diamond-shaped stent cells), which largest one of stent cells 90A is the one of the stent cells 90 that is defined by the one or more of structural strut members 30 that completely surround proximal end 54 of lateral tube 50 at junction 60, when stent-graft 20 is in the radially-expanded state.


As mentioned above regarding stent-graft 20, for some applications, stent-graft 120 comprises two or more (e.g., exactly two or exactly three) lateral tubes 50. For these applications, lateral tube 50 is a first lateral tube 50, distal and proximal ends 52 and 54 are first distal and proximal ends 54 and 54, junction 60 is a first junction 60, lateral lumen 62 is a first lateral lumen 62, central longitudinal axis 64 is a first central longitudinal axis 64, and arcuate members 70 are first arcuate members 70. Structural strut members 30 and graft member 32 are arranged so as to define, when stent-graft 20 is in the radially-expanded state, a second lateral tube 150, which (a) has (i) a second distal end 152 and (ii) a second proximal end 154 that is joined to lateral wall 56 of main tube 40 at a second junction 160, (b) is shaped so as to define a second lateral lumen 162 that is in fluid communication with main lumen 42, and (c) defines a second central longitudinal axis 164. When stent-graft 20 is in the radially-expanded state, structural strut members 30 that define second lateral tube 150 are shaped so as to define two to four non-contiguous second arcuate members 170, which (a) are centered around second central longitudinal axis 164, and (c) collectively subtend at least 150 degrees around second central longitudinal axis 164.


For some applications, the smallest one of stent cells 90B (e.g., the diamond-shaped stent cells) completely surrounds second proximal end 154 of second lateral tube 150 at second junction 160, when stent-graft 20 is in the radially-expanded state. For some applications, an average circumference of second lateral tube 150 is less than an average circumference of first lateral tube 50.


For other applications, such as shown in FIGS. 6A-B, structural strut members 30 and graft member 32 are arranged so as to define, when stent-graft 20 is in the radially-expanded state, second lateral tube 150, and the smallest one of stent cells 90B (e.g., the diamond-shaped stent cells) does not surround second proximal end 154 of second lateral tube 150 at second junction 160, when stent-graft 20 is in the radially-expanded state. For these applications, an average circumference of second lateral tube 150 may be equal to an average circumference of first lateral tube 50.


Reference is now made to FIGS. 4A and 4B, which are schematic illustrations of a portion of an endovascular stent-graft 220, in accordance with an application of the present invention. Stent-graft 220 may implement any of the features of stent-graft 20, described hereinabove with reference to FIGS. 1A-B and 2A-B, and/or stent-graft 120, described hereinabove with reference to FIGS. 3A-B.


As mentioned above, for some applications, structural strut members 30 that define lateral tube 50 are shaped so as to define respective linking members 84 for arcuate members 70, which linking members 84 link arcuate members 70 to junction 60, such as with the one or more structural strut members 86 that surround proximal end 54, for applications in which these surrounding strut members are provided. For some applications, such as shown in FIG. 4A, linking members 84 form respective angles γ (gamma) with the respective arcuate members 70, which angles have an average of 30 to 60 degrees (e.g., about 45 degrees), when stent-graft 20 is in the radially-expanded state. For some applications, proximal portions of linking members 84 are generally asymptotic with junction 60, and with the one or more structural strut members 86 that surround proximal end 54, for applications in which these surrounding strut members are provided.


In this configuration, distal end 52 of lateral tube 50 rotates during the transition from the compressed delivery state to the radially-expanded state. As a result, in the crimped configuration shown in FIG. 4B (in which lateral tube is in the radially-compressed state thereof), linking members 84 do not overlap one another, which might cause an increased crossing profile of stent-graft 220.


For some applications, one or more (e.g., all) of arcuate members 70 are shaped so as to define respective jointed locations 292, which are configured such that the arcuate members fold at the jointed locations 292 when main tube 40 is radially compressed. Without such folding protrusions, the arcuate members might plastically deform at arbitrary locations therealong when the main tube is radially compressed. For some applications, each of the jointed locations 292 is at a location along its respective arcuate member 70 that is within a number of degrees of a circumferential center 294 of the arcuate member around central longitudinal axis 64, which number of degrees is equal to 40% of a total number of degrees of the arcuate member, such as at the circumferential center of the arcuate member. For some applications, arcuate members 70 of stent-graft 20 or 120, described hereinabove with reference to FIGS. 1A-3B, are shaped so as to define respective jointed locations 292.


For some applications, stent-graft 220 comprises two or more (e.g., exactly two or exactly three) lateral tubes 50, such as described hereinbelow with reference to FIGS. 3A-B, mutatis mutandis.


Reference is now made to FIGS. 5A and 5B, which are schematic illustrations of portions of stent-grafts 20 and 220, respectively, in accordance with respective applications of the present invention. As mentioned above, for some applications, structural strut members 30 that define lateral tube 50 are shaped so as to define respective linking members 84 for arcuate members 70, which linking members 84 link arcuate members 70 to junction 60.


For some applications, as shown in FIGS. 5A and 5B, when stent-graft 20 is in the radially-expanded state, respective points 300 on linking members 84 and respective juncture points 302 between linking members 84 and arcuate members 70 define respective lines 304 (it is to be understood that points 300 and 302 and lines 304 are not actual structural features of the stent-grafts, but are instead abstract geometric elements used to describe the physical properties of the device). Lines 304 form respective angles δ (delta) with the respective arcuate members 70. The angles δ (delta) have an average of 30 to 90 degrees. Points 300 on linking members 84 are at 30% of a distance D2 between the axial position of arcuate members 70 and junction 60. For some applications, such as shown in FIG. 5A, the average is 85 to 90 degrees, e.g., 90 degrees, while for other applications, such as shown in FIG. 5B, the average is 30 to 60 degrees, e.g., about 45 degrees.


For some applications, such as labeled in FIGS. 5A and also shown in FIGS. 1A, 2A, and 3A, juncture point 302 between each of the linking members 84 and its respective arcuate member is at a location along the arcuate member that is within a number of degrees of circumferential center 294 of the arcuate member around central longitudinal axis 64, which number of degrees is equal to 40% of a total number of degrees of the arcuate member, such as at the circumferential center of the arcuate member. For other applications, such as labeled in FIG. 5B and also shown in FIG. 4A,


Reference is now made to FIGS. 6A-B, which are schematic illustrations of exemplary deployments of stent-graft 120, in accordance with respective applications of the present invention. Stent-graft 120, and the other stent-grafts described herein, may also be used to treat a blood vessel suffering from a dissection, or, more generally, a pathologically dilated aorta. The techniques described with reference to FIGS. 6A-B may also be used to deploy stent-grafts 20 and 220.


In the configuration shown in FIG. 6A, stent-graft 120 is shown deployed in the vicinity of a sub-renal (e.g., juxtarenal) abdominal aortic aneurysm 400 of an abdominal aorta. In this deployment, an average circumference of second lateral tube 150 is equal to an average circumference of first lateral tube 50.


In the configuration shown in FIG. 6B, stent-graft 120 is shown deployed in an aortic arch 500 and a brachiocephalic artery 503. More particularly, main tube 40 is shown deployed mostly in aortic arch 500, with a narrower proximal end 510 of the main tube deployed in brachiocephalic artery 503. For some applications, a circumference of proximal end 510 of main tube 40 is 3 to 10 cm, when stent-graft 120 is in the radially-expanded state. Alternatively or additionally, for some applications, a circumference of a distal end of main tube 40 is 6 to 12 cm, when stent-graft 120 is in the radially-expanded state. Alternatively, narrower proximal end 510 of main tube 40 may be configured to be disposed in another branch of aortic arch 500, such as a left common carotid artery 512 or a left subclavian artery 514. Optionally, the techniques described herein are used in combination with the techniques described in US Patent Application Publication 2013/0013050, which is incorporated herein by reference. (It is noted that in the deployment shown in FIG. 6B, blood flow to left subclavian artery 514 is blocked by stent-graft 120. The left subclavian artery is either “sacrificed” (i.e. via occlusion), or surgically anastomosed to left common carotid artery 512, or possibly to another source artery, such as the right common carotid artery. Alternatively, stent-graft 120 may be shaped so as to define an additional lateral tube 50, and an additional branching stent-graft may be deployed into left subclavian artery 514.)


The deployment is typically performed in a transvascular (typically percutaneous) procedure using one or more guidewires and an elongate delivery tube that is sized to hold stent-graft 120 in the radially-compressed delivery state. For some applications, a ratio of (a) an average circumference of main tube 40 when in the radially-expanded state thereof to (b) an inner circumference of the delivery tube is at least 5. Typically, after stent-graft 120 is positioned at the desired anatomical site, the sheath is withdrawn proximally, exposing stent-graft 120 and allowing the stent-graft to self-expand, or be expanded by plastic deformation using a balloon, into the radially-expanded state. The deployment may be performed using deployment techniques known in the art and/or described in any of the patent applications publications and patents incorporated hereinbelow by reference.


For some applications, such as shown in FIG. 6A, first and second lateral tubes 50 and 150 are positioned in respective branching blood vessels, such as branching visceral arteries, e.g., renal arteries 402A and 402B. For other applications, such as shown in FIG. 6B, one of first and second lateral tubes 50 and 150 is positioned in the main blood vessel and the other in a branching blood vessel, e.g., first lateral tube 50 is positioned in aortic arch 500, facing upstream, and second lateral tube 150 is positioned in brachiocephalic artery 503.


For some applications, two or more branching stent-grafts, such as two branching stent-grafts 410A and 410B, are deployed through a portion main lumen 42 of main tube 40 and through first and second lateral lumens 62 and 162 of first and second lateral tubes 50 and 150, respectively, and into their respective arteries, so as to form respective blood-tight seals with first and second lateral tubes 50 and 150. For example, as shown in FIG. 6A, branching stent-grafts 410A and 410B are positioned in renal arteries 402A and 402B, respectively, or, as shown in FIG. 6B, branching stent-grafts 410A and 410B are positioned in an ascending aorta 516 and left common carotid artery 512, respectively. For example, the branching stent-grafts may be deployed using respective guidewires and cannulae, such as described in PCT Application PCT/IL2014/050973, filed Nov. 6, 2014, which published as WO 2015/075708, and which is incorporated herein by reference, with respect to FIGS. 13E-J thereof. As a result, in the deployment shown in FIG. 6A, stent-graft 120 and branching stent-grafts 410A and 410B together define a fluid flow path through the aorta and the renal arteries, and in the deployment shown in FIG. 6B, stent-graft 120 and branching stent-grafts 410A and 410B together define a fluid flow path through aortic arch 500 and brachiocephalic artery 503 and left common carotid artery 512. Typically, the branching stent-grafts are transvascularly introduced when in respective radially-compressed delivery states, and are transitioned to respective radially-expanded states.


As mentioned above, for some applications the stent-graft is shaped so as to define one or more additional lateral tubes 50. For these applications, one or more additional branching stent-grafts may be deployed into additional branching visceral arteries, such as, for the deployment shown in FIG. 6A, the superior mesenteric artery (SMA) and/or the celiac artery, or, for the deployment shown in FIG. 6B, left subclavian artery 514, and sealingly coupled to the additional lateral tube(s). Typically, a main stent-graft is deployed and blood-tightly sealingly coupled to a proximal end of stent-graft 120 to extend the fluid flow path past the aneurysm, such as shown in FIG. 13J of the above-mentioned PCT Application PCT/IL2014/050973, mutatis mutandis. Alternatively, stent-graft 120 may be shaped so as to define a fenestration to allow blood flow to the SMA.


The scope of the present invention includes embodiments described in the following patents and patent applications, which are assigned to the assignee of the present application and are incorporated herein by reference. In an embodiment, techniques and apparatus described in one or more of the following patent applications are combined with techniques and apparatus described herein. In particular, the stent-grafts described herein may be used as components of the stent-graft systems described in the following patent and patent applications, and deployed as described as described in the following patent and patent applications, mutatis mutandis.

    • PCT Application PCT/IL2008/000287, filed Mar. 5, 2008, which published as PCT Publication WO 2008/107885
    • PCT Application PCT/IB2010/052861, filed Jun. 23, 2010, which published as PCT Publication WO 2010/150208
    • PCT Application PCT/IL2010/000564, filed Jul. 14, 2010, which published as PCT Publication WO 2011/007354
    • PCT Application PCT/IL2010/000917, filed Nov. 4, 2010, which published as PCT Publication WO 2011/055364
    • PCT Application PCT/IL2010/000999, filed Nov. 30, 2010, which published as PCT Publication WO 2011/064782
    • PCT Application PCT/IL2010/001018, filed Dec. 2, 2010, which published as PCT Publication WO 2011/067764
    • PCT Application PCT/IL2010/001037, filed Dec. 8, 2010, which published as PCT Publication WO 2011/070576
    • PCT Application PCT/IL2011/000135, filed Feb. 8, 2011, which published as PCT Publication WO 2011/095979
    • PCT Application PCT/IL2012/000060, filed Feb. 2, 2012, which published as PCT Publication WO 2012/104842
    • PCT Application PCT/IL2012/000241, filed Jun. 19, 2012, which published as PCT Publication WO 2012/176187
    • PCT Application PCT/IL2012/000300, filed Aug. 12, 2012, which published as PCT Publication WO 2013/030819
    • U.S. Pat. No. 8,317,856 to Shalev et al.
    • U.S. Pat. No. 8,574,287 to Benary et al.
    • U.S. Provisional Application 60/892,885, filed Mar. 5, 2007
    • U.S. Provisional Application 60/991,726, filed Dec. 2, 2007
    • U.S. Provisional Application 61/219,758, filed Jun. 23, 2009
    • U.S. Provisional Application 61/221,074, filed Jun. 28, 2009
    • U.S. application Ser. No. 13/031,871, filed Feb. 22, 2011, which published as US Patent Application Publication 2011/0208289
    • U.S. Provisional Application 61/496,613, filed Jun. 14, 2011
    • U.S. Provisional Application 61/499,195, filed Jun. 21, 2011
    • U.S. Provisional Application 61/505,132, filed Jul. 7, 2011
    • U.S. Provisional Application 61/529,931, filed Sep. 1, 2011
    • U.S. Provisional Application 61/553,209, filed Oct. 30, 2011
    • U.S. application Ser. No. 13/380,278, filed Dec. 22, 2011, which published as US Patent Application Publication 2012/0150274
    • U.S. application Ser. No. 13/384,075, filed Jan. 13, 2012, which published as US Patent Application Publication 2012/0179236
    • U.S. application Ser. No. 13/505,996, filed May 3, 2012, which published as US Patent Application Publication 2012/0310324
    • U.S. application Ser. No. 13/513,397, filed Jun. 1, 2012, which published as US Patent Application Publication 2012/0330399
    • U.S. application Ser. No. 13/514,240, filed Jun. 6, 2012, which published as US Patent Application Publication 2013/0013051
    • U.S. Provisional Application 61/678,182, filed Aug. 1, 2012
    • U.S. application Ser. No. 13/577,161, filed Aug. 3, 2012, which published as US Patent Application Publication 2013/0035751
    • U.S. application Ser. No. 13/512,778, filed Sep. 24, 2012, which published as US Patent Application Publication 2013/0013050
    • U.S. application Ser. No. 13/807,880, filed Dec. 31, 2012, which published as US Patent Application Publication 2013/0131783
    • PCT Application PCT/IL2012/000095, filed Mar. 1, 2012, which published as PCT Publication WO 2012/117395
    • PCT Application PCT/IL2012/000148, filed Apr. 4, 2012, which published as PCT Publication WO 2013/030818
    • PCT Application PCT/IL2012/000190, filed May 15, 2012, which published as PCT Publication WO 2013/171730
    • PCT Application PCT/IL2012/000269, filed Jul. 2, 2012, which published as PCT Publication WO 2013/005207
    • PCT Application PCT/IL2012/050424, filed Oct. 29, 2012, which published as PCT Publication WO 2013/065040
    • PCT Application PCT/IL2012/050506, filed Dec. 4, 2012, which published as PCT Publication WO 2013/084235
    • U.S. Provisional Application 61/749,965, filed Jan. 8, 2013
    • U.S. application Ser. No. 13/807,906, filed Feb. 8, 2013, which published as US Patent Application Publication 2013/0204343
    • U.S. Provisional Application 61/775,964, filed Mar. 11, 2013
    • U.S. Provisional Application 61/826,544, filed May 23, 2013
    • U.S. application Ser. No. 13/979,551, filed Jul. 12, 2013, which published as US Patent Application Publication 2013/0289587
    • PCT Application PCT/IL2013/050656, filed Jul. 31, 2013, which published as PCT Publication WO 2014/020609
    • U.S. Provisional Application 61/906,014, filed Nov. 19, 2013
    • PCT Application PCT/IL2014/050019, filed Jan. 7, 2014, which published as PCT Publication WO 2014/108895
    • U.S. Provisional Application 61/926,533, filed Jan. 13, 2014
    • PCT Application PCT/IL2014/050174, filed Feb. 18, 2014, which published as PCT Publication WO 2014/141232
    • PCT Application PCT/IL2014/050434, filed May 18, 2014, which published as PCT Publication WO 2014/188412
    • PCT Application PCT/IL2014/050973, filed Nov. 6, 2014, which published as PCT Publication WO 2015/075708


It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described hereinabove. Rather, the scope of the present invention includes both combinations and subcombinations of the various features described hereinabove, as well as variations and modifications thereof that are not in the prior art, which would occur to persons skilled in the art upon reading the foregoing description.

Claims
  • 1. Apparatus comprising an endovascular stent-graft, which is configured to transition from a radially-compressed delivery state to a radially-expanded state, and which comprises: a plurality of structural strut members; anda graft member, which comprises one or more substantially blood-impervious flexible sheets, and which is fixed to the structural strut members,wherein the structural strut members and the graft member are arranged so as to define, when the stent-graft is in the radially-expanded state: a main tube, which is shaped so as to define a main lumen, anda lateral tube, which (a) has (i) a distal end and (ii) a proximal end that is joined to a lateral wall of the main tube at a main-tube junction, (b) is shaped so as to define a lateral lumen that is in fluid communication with the main lumen, and (c) defines a central longitudinal axis, andwherein, when the stent-graft is in the radially-expanded state, the structural strut members that define the lateral tube are shaped so as to define: (1) two to four non-contiguous arcuate members, which (a) surround the central longitudinal axis, and (b) collectively subtend at least 150 degrees around the central longitudinal axis, and (2) respective linking members for the arcuate members,wherein the linking members link the arcuate members to the main-tube junction,wherein the linking members form respective angles with the respective arcuate members at respective linking-arcuate-member junction points between the linking members and the respective arcuate members, andwherein the stent-graft is configured such that the angles increase during a transition of the lateral tube from a compressed delivery state thereof to a radially-expanded state thereof while the main tube is in a radially-expanded state thereof.
  • 2. The apparatus according to claim 1, wherein the arcuate members collectively subtend at least 180 degrees around the central longitudinal axis, when the stent-graft is in the radially-expanded state.
  • 3. The apparatus according to claim 1, wherein at least one of the arcuate members alone subtends at least 60 degrees around the central longitudinal axis, when the stent-graft is in the radially-expanded state.
  • 4. The apparatus according to claim 1, wherein the arcuate members are disposed at a distal end of a portion of the graft member that defines the lateral tube, when the stent-graft is in the radially-expanded state.
  • 5. The apparatus according to claim 1, wherein when the main tube is in the radially-expanded state thereof and the lateral tube is in the compressed delivery state thereof, the arcuate members define a portion of a generally tubular outer surface of the main tube.
  • 6. The apparatus according to claim 1, wherein the apparatus further comprises a branching stent-graft, which is configured to form a blood-tight seal with the lateral tube, when the stent-graft is in the radially-expanded state and the branching stent-graft is in a radially-expanded state.
  • 7. The apparatus according to claim 1, wherein the arcuate members are arranged so as to provide respective circumferential gaps between circumferentially-adjacent ones of the arcuate members, when the stent-graft is in the radially-expanded state, andwherein the arcuate members collectively subtend no more than 350 degrees around the central longitudinal axis, when the stent-graft is in the radially-expanded state.
  • 8. The apparatus according to claim 1, wherein, when the stent-graft is in the radially-expanded state, one or more of the structural strut members (a) completely surround the proximal end of the lateral tube at the main-tube junction and (b) are connected to the linking members.
  • 9. The apparatus according to claim 1, wherein the arcuate members are curved around portions of the respective linking members when the stent-graft is in the radially-compressed delivery state.
  • 10. The apparatus according to claim 1, wherein the arcuate members run alongside portions of the respective linking members when the stent-graft is in the radially-compressed delivery state.
  • 11. The apparatus according to claim 1, wherein the stent-graft is configured such that, for each of the arcuate members, throughout the transition, a plane defined by the arcuate member defines a constant angle with respect to the central longitudinal axis of the lateral tube.
  • 12. The apparatus according to claim 11, wherein the stent-graft is configured such that, throughout the transition, the arcuate members collectively define the plane, which defines the constant angle with respect to the central longitudinal axis of the lateral tube.
  • 13. The apparatus according to claim 1, wherein the arcuate members are centered around the central longitudinal axis, when the stent-graft is in the radially-expanded state.
  • 14. The apparatus according to claim 1, wherein the stent-graft is configured such that the angles increase to an average of no more than 60 degrees during the transition.
  • 15. The apparatus according to claim 14, wherein the stent-graft is configured such that the angles increase to an average of 30 to 60 degrees during the transition.
  • 16. The apparatus according to claim 1, wherein the stent-graft is configured such that the angles increase to an average of at least 30 degrees during the transition.
  • 17. The apparatus according to claim 1, wherein the stent-graft is configured such that each of the linking members runs monotonically around the central longitudinal axis.
  • 18. Apparatus comprising an endovascular stent-graft, which is configured to transition from a radially-compressed delivery state to a radially-expanded state, and which comprises: a plurality of structural strut members; anda graft member, which comprises one or more substantially blood-impervious flexible sheets, and which is fixed to the structural strut members,wherein the structural strut members and the graft member are arranged so as to define, when the stent-graft is in the radially-expanded state: a main tube, which is shaped so as to define a main lumen, anda lateral tube, which (a) has (i) a distal end and (ii) a proximal end that is joined to a lateral wall of the main tube at a main-tube junction, (b) is shaped so as to define a lateral lumen that is in fluid communication with the main lumen, and (c) defines a central longitudinal axis,wherein, when the stent-graft is in the radially-expanded state, the structural strut members that define the lateral tube are shaped so as to define two to four non-contiguous arcuate members, which (a) surround the central longitudinal axis and (b) collectively subtend at least 150 degrees around the central longitudinal axis,wherein the stent-graft is configured such that, for each of the arcuate members, throughout a transition of the lateral tube from a compressed delivery state thereof to a radially-expanded state thereof while the main tube is in a radially-expanded state thereof, a plane defined by the arcuate member defines a constant angle with respect to the central longitudinal axis of the lateral tube,wherein the structural strut members that define the lateral tube are shaped so as to define respective linking members for the arcuate members, which linking members link the arcuate members to the main-tube junction, andwherein the stent-graft is configured such that each of the linking members runs monotonically around the central longitudinal axis.
  • 19. The apparatus according to claim 18, wherein the stent-graft is configured such that, throughout the transition, the arcuate members collectively define the plane, which defines the constant angle with respect to the central longitudinal axis of the lateral tube.
  • 20. The apparatus according to claim 18, wherein the arcuate members collectively subtend at least 180 degrees around the central longitudinal axis, when the stent-graft is in the radially-expanded state.
  • 21. The apparatus according to claim 18, wherein at least one of the arcuate members alone subtends at least 60 degrees around the central longitudinal axis, when the stent-graft is in the radially-expanded state.
  • 22. The apparatus according to claim 18, wherein the arcuate members are disposed at a distal end of a portion of the graft member that defines the lateral tube, when the stent-graft is in the radially-expanded state.
  • 23. The apparatus according to claim 18, wherein when the main tube is in the radially-expanded state thereof and the lateral tube is in the compressed delivery state thereof, the arcuate members define a portion of a generally tubular outer surface of the main tube.
  • 24. The apparatus according to claim 18, wherein the apparatus further comprises a branching stent-graft, which is configured to form a blood-tight seal with the lateral tube, when the stent-graft is in the radially-expanded state and the branching stent-graft is in a radially-expanded state.
  • 25. The apparatus according to claim 18, wherein the arcuate members are arranged so as to provide respective circumferential gaps between circumferentially-adjacent ones of the arcuate members, when the stent-graft is in the radially-expanded state, andwherein the arcuate members collectively subtend no more than 350 degrees around the central longitudinal axis, when the stent-graft is in the radially-expanded state.
  • 26. The apparatus according to claim 18, wherein, when the stent-graft is in the radially-expanded state, one or more of the structural strut members (a) completely surround the proximal end of the lateral tube at the main-tube junction and (b) are connected to the linking members.
CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a continuation of U.S. application Ser. No. 16/668,045, filed Oct. 30, 2019, now U.S. Pat. No. 11,419,742, which is a continuation of U.S. application Ser. No. 15/105,106, filed Jun. 16, 2016, now U.S. Pat. No. 10,485,684, which is the US national stage of International Application PCT/IL2015/051221, filed Dec. 16, 2015, which claims priority from U.S. Provisional Application 62/093,497, filed Dec. 18, 2014, which is assigned to the assignee of the present application and is incorporated herein by reference.

US Referenced Citations (640)
Number Name Date Kind
4180613 Vassiliou Dec 1979 A
4355426 MacGregor Oct 1982 A
4505767 Quin Mar 1985 A
4562596 Kornberg Jan 1986 A
4577631 Kreamer Mar 1986 A
4617932 Kornberg Oct 1986 A
4665906 Jervis May 1987 A
4739762 Palmaz Apr 1988 A
4787899 Lazarus Nov 1988 A
4816339 Tu et al. Mar 1989 A
4878906 Lindemann et al. Nov 1989 A
4886062 Wiktor Dec 1989 A
4938740 Melbin Jul 1990 A
4969458 Wiktor Nov 1990 A
5042707 Taheri Aug 1991 A
5064435 Porter Nov 1991 A
5104404 Wolff Apr 1992 A
5122136 Guglielmi et al. Jun 1992 A
5129910 Phan et al. Jul 1992 A
5133732 Wiktor Jul 1992 A
5192256 Ryan Mar 1993 A
5192286 Phan et al. Mar 1993 A
5234448 Wholey et al. Aug 1993 A
5383926 Lock et al. Jan 1995 A
5425739 Jessen Jun 1995 A
5425765 Tiefenbrun et al. Jun 1995 A
5439446 Barry Aug 1995 A
5456694 Marin et al. Oct 1995 A
5486183 Middleman et al. Jan 1996 A
5507769 Marin et al. Apr 1996 A
5509923 Middleman et al. Apr 1996 A
5522880 Barone et al. Jun 1996 A
5527322 Klein et al. Jun 1996 A
5549662 Fordenbacher Aug 1996 A
5554181 Das Sep 1996 A
5556413 Lam Sep 1996 A
5562724 Vorwerk et al. Oct 1996 A
5575818 Pinchuk Nov 1996 A
5607445 Summers Mar 1997 A
5613974 Andreas et al. Mar 1997 A
5632746 Middleman et al. May 1997 A
5632763 Glastra May 1997 A
5632772 Alcime et al. May 1997 A
5639278 Dereume et al. Jun 1997 A
5643340 Nunokawa Jul 1997 A
5653743 Martin Aug 1997 A
5676696 Marcade Oct 1997 A
5676697 McDonald Oct 1997 A
5693084 Chuter Dec 1997 A
5728134 Barak Mar 1998 A
5749825 Fischell et al. May 1998 A
5749879 Middleman et al. May 1998 A
5755770 Ravenscroft May 1998 A
5755771 Penn et al. May 1998 A
5755774 Pinchuk May 1998 A
5755777 Chuter May 1998 A
5755781 Jayaraman May 1998 A
5769882 Fogarty et al. Jun 1998 A
5769884 Solovay Jun 1998 A
5782903 Wiktor Jul 1998 A
5782906 Marshall et al. Jul 1998 A
5824040 Cox et al. Oct 1998 A
5824055 Spiridigliozzi et al. Oct 1998 A
5827321 Roubin Oct 1998 A
5843170 Ahn Dec 1998 A
5855600 Alt Jan 1999 A
5860991 Klein et al. Jan 1999 A
5876432 Lau et al. Mar 1999 A
5906641 Thompson et al. May 1999 A
5921994 Andreas et al. Jul 1999 A
5925076 Inoue Jul 1999 A
5944750 Tanner et al. Aug 1999 A
5948018 Dereume et al. Sep 1999 A
5968091 Pinchuk et al. Oct 1999 A
5972017 Berg et al. Oct 1999 A
5976178 Goldsteen et al. Nov 1999 A
5980552 Pinchasik Nov 1999 A
5984955 Wisselink Nov 1999 A
6015431 Thornton et al. Jan 2000 A
6016810 Ravenscroft Jan 2000 A
6030414 Taheri Feb 2000 A
6033435 Penn et al. Mar 2000 A
6036723 Anidjar et al. Mar 2000 A
6036725 Avellanet Mar 2000 A
6051021 Frid Apr 2000 A
6059824 Taheri May 2000 A
6077298 Tu et al. Jun 2000 A
6099497 Adams et al. Aug 2000 A
6099548 Taheri Aug 2000 A
6117145 Wood et al. Sep 2000 A
6129738 Lashinski et al. Oct 2000 A
6132457 Chobotov Oct 2000 A
6152937 Peterson et al. Nov 2000 A
6152956 Pierce Nov 2000 A
6156064 Chouinard Dec 2000 A
6159228 Frid et al. Dec 2000 A
6168615 Ken et al. Jan 2001 B1
6176875 Lenker et al. Jan 2001 B1
6179878 Duerig et al. Jan 2001 B1
6200339 Leschinsky et al. Mar 2001 B1
6206893 Klein et al. Mar 2001 B1
6270524 Kim Aug 2001 B1
6283991 Cox et al. Sep 2001 B1
6287335 Drasler et al. Sep 2001 B1
6290720 Khosravi et al. Sep 2001 B1
6296661 Davila et al. Oct 2001 B1
6312458 Golds Nov 2001 B1
6319287 Frimberger Nov 2001 B1
6325819 Pavcnik et al. Dec 2001 B1
6325823 Horzewski et al. Dec 2001 B1
6325826 Vardi et al. Dec 2001 B1
6344056 Dehdashtian Feb 2002 B1
6395018 Castaneda May 2002 B1
6406420 McCarthy Jun 2002 B1
6428565 Wisselink Aug 2002 B1
6451048 Berg et al. Sep 2002 B1
6451051 Drasler et al. Sep 2002 B2
6471722 Inoue Oct 2002 B1
6506211 Skubitz et al. Jan 2003 B1
6520988 Colombo et al. Feb 2003 B1
6544279 Hopkins et al. Apr 2003 B1
6565597 Fearnot et al. May 2003 B1
6576009 Ryan et al. Jun 2003 B2
6613075 Healy et al. Sep 2003 B1
6613078 Barone Sep 2003 B1
6635083 Cheng et al. Oct 2003 B1
6645242 Quinn Nov 2003 B1
6648901 Fleischman et al. Nov 2003 B2
6648911 Sirhan Nov 2003 B1
6652567 Deaton Nov 2003 B1
6652571 White et al. Nov 2003 B1
6656214 Fogarty et al. Dec 2003 B1
6673080 Reynolds et al. Jan 2004 B2
6692520 Gambale et al. Feb 2004 B1
6695833 Frantzen Feb 2004 B1
6695875 Stelter et al. Feb 2004 B2
6699277 Freidberg et al. Mar 2004 B1
6716238 Elliot Apr 2004 B2
6729356 Baker et al. May 2004 B1
6730117 Tseng et al. May 2004 B1
6733523 Shaolian et al. May 2004 B2
6743195 Zucker Jun 2004 B2
6748953 Sherry et al. Jun 2004 B2
6752826 Wholey et al. Jun 2004 B2
6776794 Hong et al. Aug 2004 B1
6808534 Escano Oct 2004 B1
6814749 Cox et al. Nov 2004 B2
6814752 Chuter Nov 2004 B1
6824560 Pelton Nov 2004 B2
6843803 Ryan et al. Jan 2005 B2
6846321 Zucker Jan 2005 B2
6860900 Clerc et al. Mar 2005 B2
6907285 Denker et al. Jun 2005 B2
6908477 McGuckin, Jr. et al. Jun 2005 B2
6929660 Ainsworth et al. Aug 2005 B1
6942691 Chuter Sep 2005 B1
6953469 Ryan Oct 2005 B2
6964679 Marcade et al. Nov 2005 B1
6986774 Middleman et al. Jan 2006 B2
7008441 Zucker Mar 2006 B2
7018400 Lashinski et al. Mar 2006 B2
7022131 DeRowe et al. Apr 2006 B1
7044962 Elliott May 2006 B2
7083822 Brightbill Aug 2006 B2
7105015 Goshgarian Sep 2006 B2
7105020 Greenberg et al. Sep 2006 B2
7112217 Kugler et al. Sep 2006 B1
7115127 Lindenbaum et al. Oct 2006 B2
7122052 Greenhalgh Oct 2006 B2
7131991 Zarins et al. Nov 2006 B2
7144421 Carpenter et al. Dec 2006 B2
7160318 Greenberg et al. Jan 2007 B2
7175651 Kerr Feb 2007 B2
7198638 Dong Apr 2007 B2
7201772 Schwammenthal et al. Apr 2007 B2
7220274 Quinn May 2007 B1
7223266 Lindenbaum et al. May 2007 B2
7261733 Brown et al. Aug 2007 B1
7270675 Chun et al. Sep 2007 B2
7279003 Berra et al. Oct 2007 B2
7294145 Ward Nov 2007 B2
7294147 Hartley Nov 2007 B2
7306623 Watson Dec 2007 B2
7341598 Davidson et al. Mar 2008 B2
7393357 Stelter et al. Jul 2008 B2
7396363 Frid Jul 2008 B2
7399313 Brown et al. Jul 2008 B2
7407509 Greenberg et al. Aug 2008 B2
7413573 Hartley et al. Aug 2008 B2
7425219 Quadri Sep 2008 B2
7429269 Schwammenthal et al. Sep 2008 B2
7438721 Doig et al. Oct 2008 B2
7442204 Schwammenthal et al. Oct 2008 B2
7473272 Pryor Jan 2009 B2
7491231 Nazzaro et al. Feb 2009 B2
7537606 Hartley et al. May 2009 B2
7537609 Davidson et al. May 2009 B2
7540881 Meyer et al. Jun 2009 B2
7544160 Gross Jun 2009 B2
7575590 Watson Aug 2009 B2
7616997 Kieval et al. Nov 2009 B2
7637939 Tischler Dec 2009 B2
7645298 Hartley et al. Jan 2010 B2
7662161 Briganti et al. Feb 2010 B2
7662168 McGuckin, Jr. et al. Feb 2010 B2
7670369 Schaeffer Mar 2010 B2
7678141 Greenan et al. Mar 2010 B2
7699885 Leonhardt et al. Apr 2010 B2
7708704 Mitelberg May 2010 B2
7722626 Middleman et al. May 2010 B2
7731732 Ken Jun 2010 B2
7766955 Vardi et al. Aug 2010 B2
7771465 Zukowski Aug 2010 B2
7789903 Spiridigliozzi et al. Sep 2010 B2
7803177 Hartley et al. Sep 2010 B2
7803178 Whirley Sep 2010 B2
7806923 Moloney Oct 2010 B2
7815673 Bloom et al. Oct 2010 B2
7833259 Boatman Nov 2010 B2
7833264 Hegg et al. Nov 2010 B2
7833266 Gregorich et al. Nov 2010 B2
7842081 Yadin Nov 2010 B2
7846194 Hartley et al. Dec 2010 B2
7850725 Vardi et al. Dec 2010 B2
7867270 Hartley et al. Jan 2011 B2
7887575 Kujawski Feb 2011 B2
7914572 Hartley et al. Mar 2011 B2
7955373 Sowinski et al. Jun 2011 B2
7955374 Erickson et al. Jun 2011 B2
7959662 Erbel et al. Jun 2011 B2
7959668 Yadin Jun 2011 B2
7959669 Chalekian et al. Jun 2011 B2
7998186 Hartley Aug 2011 B2
7998187 Hartley et al. Aug 2011 B2
8012193 Hartley et al. Sep 2011 B2
8016853 Griffen et al. Sep 2011 B2
8021412 Hartley et al. Sep 2011 B2
8021418 Gerberding et al. Sep 2011 B2
8021419 Hartley et al. Sep 2011 B2
8043365 Thramann Oct 2011 B2
8048139 Frid et al. Nov 2011 B2
8048140 Purdy Nov 2011 B2
8048147 Adams Nov 2011 B2
8052736 Doig et al. Nov 2011 B2
8052741 Bruszewski et al. Nov 2011 B2
8066755 Zacharias Nov 2011 B2
8080026 Konstantino et al. Dec 2011 B2
8080053 Satasiya Dec 2011 B2
8100960 Bruszewski Jan 2012 B2
8118854 Bowe Feb 2012 B2
8133267 Leonhardt et al. Mar 2012 B2
8157810 Case et al. Apr 2012 B2
8167926 Hartley et al. May 2012 B2
8172892 Chuter May 2012 B2
8172895 Anderson et al. May 2012 B2
8197475 Bruszewski et al. Jun 2012 B2
8197533 Kujawski Jun 2012 B2
8211158 Wolf Jul 2012 B2
8216298 Wright et al. Jul 2012 B2
8221494 Schreck et al. Jul 2012 B2
8226706 Hartley et al. Jul 2012 B2
8236040 Mayberry et al. Aug 2012 B2
8251963 Chin et al. Aug 2012 B2
8257423 Kerr Sep 2012 B2
8262719 Erickson et al. Sep 2012 B2
8273115 Hamer et al. Sep 2012 B2
8277501 Chalekian et al. Oct 2012 B2
8287586 Schaeffer et al. Oct 2012 B2
8292885 Bruszewski et al. Oct 2012 B2
8292941 Muzslay Oct 2012 B2
8292949 Berra et al. Oct 2012 B2
8292951 Muzslay Oct 2012 B2
8333800 Bruszewski et al. Dec 2012 B2
8337546 Bruszewski Dec 2012 B2
8353898 Lutze et al. Jan 2013 B2
8357192 Mayberry et al. Jan 2013 B2
8361134 Hartley et al. Jan 2013 B2
8394136 Hartley et al. Mar 2013 B2
8425585 Melsheimer et al. Apr 2013 B2
8470018 Hartley et al. Jun 2013 B2
8475513 Sithian Jul 2013 B2
8480726 Cunningham et al. Jul 2013 B2
8486131 Shalev Jul 2013 B2
8491646 Schreck Jul 2013 B2
8506622 Bruszewski et al. Aug 2013 B2
8551158 Roeder et al. Oct 2013 B2
8728148 Roeder et al. May 2014 B2
8808355 Barrand Aug 2014 B2
8945203 Shalev et al. Feb 2015 B2
8968384 Pearson et al. Mar 2015 B2
9101457 Benary Aug 2015 B2
9168123 Barrand Oct 2015 B2
9254209 Shalev Feb 2016 B2
9351822 Roeder May 2016 B2
9597204 Benary et al. Mar 2017 B2
9907680 Skender Mar 2018 B2
10485684 Marmur et al. Nov 2019 B2
20010000188 Lenker et al. Apr 2001 A1
20010003161 Vardi et al. Jun 2001 A1
20010004705 Killion Jun 2001 A1
20010010006 Bachinski et al. Jul 2001 A1
20010014823 Resseman et al. Aug 2001 A1
20010034550 Buirge Oct 2001 A1
20010037142 Stelter et al. Nov 2001 A1
20010044647 Pinchuk et al. Nov 2001 A1
20010044651 Steinke Nov 2001 A1
20010044652 Moore Nov 2001 A1
20010047198 Drasler Nov 2001 A1
20010049550 Martin et al. Dec 2001 A1
20010053930 Kugler et al. Dec 2001 A1
20020040236 Lau Apr 2002 A1
20020052643 Wholey et al. May 2002 A1
20020052644 Shaolian et al. May 2002 A1
20020072790 McGuckin et al. Jun 2002 A1
20020099438 Furst Jul 2002 A1
20020099441 Dehdashtian Jul 2002 A1
20020107564 Cox Aug 2002 A1
20020111667 Girton et al. Aug 2002 A1
20020123791 Harrison Sep 2002 A1
20020156495 Brenneman et al. Oct 2002 A1
20020156517 Prouse et al. Oct 2002 A1
20020173809 Fleischman et al. Nov 2002 A1
20020173840 Brucker et al. Nov 2002 A1
20020183783 Shadduck Dec 2002 A1
20020193864 Khosravi et al. Dec 2002 A1
20020198585 Wisselink Dec 2002 A1
20030033005 Houser et al. Feb 2003 A1
20030040791 Oktay Feb 2003 A1
20030040804 Stack et al. Feb 2003 A1
20030057156 Peterson et al. Mar 2003 A1
20030065345 Weadock Apr 2003 A1
20030065386 Weadock Apr 2003 A1
20030074055 Haverkost Apr 2003 A1
20030093145 Lawrence-Brown et al. May 2003 A1
20030114061 Matsuda et al. Jun 2003 A1
20030125796 Dong Jul 2003 A1
20030130720 DePalma et al. Jul 2003 A1
20030139802 Wulfman et al. Jul 2003 A1
20030139805 Holmberg et al. Jul 2003 A1
20030144725 Lombardi Jul 2003 A1
20030153944 Phung et al. Aug 2003 A1
20030153968 Geis et al. Aug 2003 A1
20030163187 Weber Aug 2003 A1
20030171771 Anderson et al. Sep 2003 A1
20030191523 Hojeibane Oct 2003 A1
20030199967 Hartley et al. Oct 2003 A1
20030199968 Ainsworth et al. Oct 2003 A1
20030204236 Letort Oct 2003 A1
20030204242 Zarins et al. Oct 2003 A1
20030204243 Shiu Oct 2003 A1
20030208192 Truckai et al. Nov 2003 A1
20030212449 Cox Nov 2003 A1
20030233117 Adams et al. Dec 2003 A1
20030236567 Elliot Dec 2003 A1
20040015227 Vardi et al. Jan 2004 A1
20040015229 Fulkerson Jan 2004 A1
20040098091 Erbel May 2004 A1
20040106972 Deaton Jun 2004 A1
20040106978 Greenberg et al. Jun 2004 A1
20040117003 Ouriel et al. Jun 2004 A1
20040133266 Clerc et al. Jul 2004 A1
20040138735 Shaolian et al. Jul 2004 A1
20040162606 Thompson Aug 2004 A1
20040171978 Shalaby Sep 2004 A1
20040176832 Hartley et al. Sep 2004 A1
20040181149 Langlotz et al. Sep 2004 A1
20040215319 Berra et al. Oct 2004 A1
20040215320 Machek Oct 2004 A1
20040215327 Doig et al. Oct 2004 A1
20040215332 Frid Oct 2004 A1
20040260383 Stelter et al. Dec 2004 A1
20050010246 Streeter et al. Jan 2005 A1
20050033406 Barnhart et al. Feb 2005 A1
20050049678 Cocks et al. Mar 2005 A1
20050059923 Gamboa Mar 2005 A1
20050065545 Wallace Mar 2005 A1
20050070995 Zilla et al. Mar 2005 A1
20050085900 Case Apr 2005 A1
20050102018 Carpenter et al. May 2005 A1
20050102021 Osborne May 2005 A1
20050131512 Vonderwalde Jun 2005 A1
20050131517 Hartley et al. Jun 2005 A1
20050137682 Justino Jun 2005 A1
20050143802 Soykan et al. Jun 2005 A1
20050149166 Schaeffer et al. Jul 2005 A1
20050154448 Cully Jul 2005 A1
20050159803 Lad et al. Jul 2005 A1
20050165480 Jordan et al. Jul 2005 A1
20050171598 Schaeffer et al. Aug 2005 A1
20050171599 White Aug 2005 A1
20050177132 Lentz et al. Aug 2005 A1
20050177222 Mead Aug 2005 A1
20050177224 Fogarty et al. Aug 2005 A1
20050203606 VanCamp Sep 2005 A1
20050216018 Sennett et al. Sep 2005 A1
20050222649 Capuano Oct 2005 A1
20050222667 Hunt Oct 2005 A1
20050222668 Schaeffer et al. Oct 2005 A1
20050222669 Purdy Oct 2005 A1
20050228480 Douglas et al. Oct 2005 A1
20050234542 Melsheimer Oct 2005 A1
20050266042 Tseng Dec 2005 A1
20050273155 Bahler et al. Dec 2005 A1
20050283188 Loshakove et al. Dec 2005 A1
20060015170 Jones et al. Jan 2006 A1
20060030911 Letort Feb 2006 A1
20060030921 Chu Feb 2006 A1
20060052799 Middleman et al. Mar 2006 A1
20060069426 Weinberger Mar 2006 A1
20060095104 Magers et al. May 2006 A1
20060095114 Hartley et al. May 2006 A1
20060095118 Hartley May 2006 A1
20060100684 Elliott May 2006 A1
20060106406 Weinberger May 2006 A1
20060116748 Kaplan et al. Jun 2006 A1
20060149360 Schwammenthal et al. Jul 2006 A1
20060155358 LaDuca et al. Jul 2006 A1
20060155359 Watson Jul 2006 A1
20060155362 Israel Jul 2006 A1
20060155366 LaDuca et al. Jul 2006 A1
20060167476 Burdulis, Jr. et al. Jul 2006 A1
20060173528 Feld et al. Aug 2006 A1
20060173530 Das Aug 2006 A1
20060178733 Pinchuk et al. Aug 2006 A1
20060190070 Dieck et al. Aug 2006 A1
20060193892 Furst et al. Aug 2006 A1
20060212113 Shaolian et al. Sep 2006 A1
20060229709 Morris et al. Oct 2006 A1
20060241740 Vardi et al. Oct 2006 A1
20060271166 Thill et al. Nov 2006 A1
20060276882 Case et al. Dec 2006 A1
20060281966 Peacock, III Dec 2006 A1
20070016281 Melsheimer Jan 2007 A1
20070021822 Boatman Jan 2007 A1
20070027526 Demetriades et al. Feb 2007 A1
20070043425 Hartley et al. Feb 2007 A1
20070050011 Klein Mar 2007 A1
20070055326 Farley et al. Mar 2007 A1
20070055350 Erickson et al. Mar 2007 A1
20070055358 Krolik et al. Mar 2007 A1
20070055360 Hanson et al. Mar 2007 A1
20070060989 Deem et al. Mar 2007 A1
20070061002 Paul, Jr. Mar 2007 A1
20070067014 Ke et al. Mar 2007 A1
20070073373 Bonsignore Mar 2007 A1
20070088425 Schaeffer Apr 2007 A1
20070106368 Vonderwalde May 2007 A1
20070112344 Keilman May 2007 A1
20070135677 Miller et al. Jun 2007 A1
20070135904 Eidenschink et al. Jun 2007 A1
20070142896 Anderson et al. Jun 2007 A1
20070150051 Arnault de la et al. Jun 2007 A1
20070156167 Connors et al. Jul 2007 A1
20070162104 Frid Jul 2007 A1
20070167898 Peters et al. Jul 2007 A1
20070167955 Arnault De La Menardiere et al. Jul 2007 A1
20070168013 Douglas Jul 2007 A1
20070168018 Amplatz Jul 2007 A1
20070179598 Duerig Aug 2007 A1
20070185565 Schwammenthal et al. Aug 2007 A1
20070207186 Scanlon et al. Sep 2007 A1
20070208410 Berra et al. Sep 2007 A1
20070208419 Meyer et al. Sep 2007 A1
20070213805 Schaeffer et al. Sep 2007 A1
20070213807 Roubin Sep 2007 A1
20070219610 Israel Sep 2007 A1
20070219614 Hartley Sep 2007 A1
20070219627 Chu Sep 2007 A1
20070225797 Krivoruhko Sep 2007 A1
20070233229 Berra et al. Oct 2007 A1
20070237973 Purdy et al. Oct 2007 A1
20070239256 Weber et al. Oct 2007 A1
20070244542 Greenan et al. Oct 2007 A1
20070244543 Mitchell Oct 2007 A1
20070244547 Greenan Oct 2007 A1
20070250154 Greenberg Oct 2007 A1
20070255388 Rudakov et al. Nov 2007 A1
20080002871 Gunzert-Marx et al. Jan 2008 A1
20080015673 Chuter Jan 2008 A1
20080015682 Majercak et al. Jan 2008 A1
20080033527 Nunez et al. Feb 2008 A1
20080058918 Watson Mar 2008 A1
20080064957 Spence Mar 2008 A1
20080086193 Thramann Apr 2008 A1
20080097578 Erickson et al. Apr 2008 A1
20080109058 Greenberg et al. May 2008 A1
20080109066 Quinn May 2008 A1
20080114444 Yu May 2008 A1
20080114445 Melsheimer et al. May 2008 A1
20080114446 Hartley et al. May 2008 A1
20080140178 Rasmussen et al. Jun 2008 A1
20080147173 McIff et al. Jun 2008 A1
20080167704 Wright et al. Jul 2008 A1
20080176271 Silver et al. Jul 2008 A1
20080195190 Bland et al. Aug 2008 A1
20080195191 Luo Aug 2008 A1
20080215134 Lawrence-Brown Sep 2008 A1
20080249598 Sherry Oct 2008 A1
20080262595 Chu et al. Oct 2008 A1
20080262598 Elmaleh Oct 2008 A1
20080269789 Eli Oct 2008 A1
20080275540 Wen Nov 2008 A1
20080275542 LaDuca et al. Nov 2008 A1
20080288044 Osborne Nov 2008 A1
20080294234 Hartley et al. Nov 2008 A1
20080300665 Lootz Dec 2008 A1
20080312732 Hartley et al. Dec 2008 A1
20080319528 Yribarren et al. Dec 2008 A1
20090012597 Doig et al. Jan 2009 A1
20090012602 Quadri Jan 2009 A1
20090030497 Metcalf et al. Jan 2009 A1
20090030502 Sun et al. Jan 2009 A1
20090048663 Greenberg Feb 2009 A1
20090054967 Das Feb 2009 A1
20090062899 Dang Mar 2009 A1
20090069881 Chalekian et al. Mar 2009 A1
20090069882 Venturelli Mar 2009 A1
20090082841 Zacharias Mar 2009 A1
20090082847 Zacharias et al. Mar 2009 A1
20090099640 Weng Apr 2009 A1
20090099647 Glimsdale et al. Apr 2009 A1
20090099648 Yu Apr 2009 A1
20090099649 Chobotov et al. Apr 2009 A1
20090099650 Bolduc et al. Apr 2009 A1
20090105809 Lee et al. Apr 2009 A1
20090112233 Xiao Apr 2009 A1
20090125096 Chu et al. May 2009 A1
20090138067 Pinchuk et al. May 2009 A1
20090149877 Hanson et al. Jun 2009 A1
20090157014 Osborne et al. Jun 2009 A1
20090163993 Chalekian et al. Jun 2009 A1
20090164001 Biggs et al. Jun 2009 A1
20090171437 Brocker et al. Jul 2009 A1
20090182270 Nanavati Jul 2009 A1
20090182405 Arnault De La Menardiere et al. Jul 2009 A1
20090192587 Frid Jul 2009 A1
20090227997 Wang Sep 2009 A1
20090240316 Bruszewski Sep 2009 A1
20090248134 Dierking et al. Oct 2009 A1
20090254170 Hartley et al. Oct 2009 A1
20090259290 Bruszewski et al. Oct 2009 A1
20090287145 Cragg et al. Nov 2009 A1
20090319022 Hartley et al. Dec 2009 A1
20100004728 Rao Jan 2010 A1
20100029608 Finley Feb 2010 A1
20100057186 West et al. Mar 2010 A1
20100063575 Shalev Mar 2010 A1
20100070019 Shalev Mar 2010 A1
20100082091 Berez Apr 2010 A1
20100161025 Kuppurathanam et al. Jun 2010 A1
20100161026 Brocker et al. Jun 2010 A1
20100161028 Chuter et al. Jun 2010 A1
20100168838 Hartley et al. Jul 2010 A1
20100211159 Schmid Aug 2010 A1
20100249899 Chuter et al. Sep 2010 A1
20100256725 Rasmussen Oct 2010 A1
20100262227 Rangwala et al. Oct 2010 A1
20100268327 Bruszewski et al. Oct 2010 A1
20100274187 Argentine Oct 2010 A1
20100274345 Rust Oct 2010 A1
20100292774 Shalev Nov 2010 A1
20100312326 Chuter et al. Dec 2010 A1
20100318171 Porter Dec 2010 A1
20100318180 Porter Dec 2010 A1
20110022149 Cox et al. Jan 2011 A1
20110022153 Schreck et al. Jan 2011 A1
20110040366 Goetz et al. Feb 2011 A1
20110093002 Rucker et al. Apr 2011 A1
20110125251 Cottone May 2011 A1
20110152998 Berez et al. Jun 2011 A1
20110208289 Shalev Aug 2011 A1
20110208296 Duffy et al. Aug 2011 A1
20110208297 Tuval et al. Aug 2011 A1
20110208298 Tuval et al. Aug 2011 A1
20110218607 Arbefeuille et al. Sep 2011 A1
20110218609 Chobotov et al. Sep 2011 A1
20110218617 Nguyen et al. Sep 2011 A1
20110319983 Zhu et al. Sep 2011 A1
20110257720 Peterson et al. Oct 2011 A1
20110257725 Argentine et al. Oct 2011 A1
20110262684 Wintsch et al. Oct 2011 A1
20110264184 Heltai Oct 2011 A1
20110264192 Hartley et al. Oct 2011 A1
20110270380 Bruszewski Nov 2011 A1
20110270385 Muzslay Nov 2011 A1
20110288622 Chan et al. Nov 2011 A1
20110301702 Rust et al. Dec 2011 A1
20120143317 Cam et al. Jun 2012 A1
20120150274 Shalev et al. Jun 2012 A1
20120158038 Leschinsky Jun 2012 A1
20120172929 Shalev Jul 2012 A1
20120172965 Kratzberg et al. Jul 2012 A1
20120179236 Benary Jul 2012 A1
20120185031 Ryan et al. Jul 2012 A1
20120271401 Bruszewski et al. Oct 2012 A1
20120310324 Benary et al. Dec 2012 A1
20120316634 Shalev et al. Dec 2012 A1
20120323305 Benary et al. Dec 2012 A1
20120330399 Shalev et al. Dec 2012 A1
20130013050 Shalev et al. Jan 2013 A1
20130013051 Benary Jan 2013 A1
20130035751 Shalev Feb 2013 A1
20130079870 Roeder et al. Mar 2013 A1
20130090722 Shalev et al. Apr 2013 A1
20130116773 Roeder et al. May 2013 A1
20130116775 Roeder et al. May 2013 A1
20130131783 Shalev et al. May 2013 A1
20130158646 Roeder Jun 2013 A1
20130197454 Shibata et al. Aug 2013 A1
20130204311 Kunis Aug 2013 A1
20130204343 Shalev Aug 2013 A1
20130261994 Raz et al. Oct 2013 A1
20130274866 Cox et al. Oct 2013 A1
20130289587 Shalev Oct 2013 A1
20130297005 Shalev Nov 2013 A1
20130338753 Geusen Dec 2013 A1
20140005764 Schroeder Jan 2014 A1
20140052236 Shalev Feb 2014 A1
20140148888 Barrand May 2014 A1
20140172072 Shalev Jun 2014 A1
20140180378 Roeder Jun 2014 A1
20140288634 Shalev Sep 2014 A1
20140288635 Shalev Sep 2014 A1
20140316510 Berra Oct 2014 A1
20140324154 Shalev Oct 2014 A1
20140350658 Benary et al. Nov 2014 A1
20140364930 Strauss et al. Dec 2014 A1
20150073534 Roeder et al. Mar 2015 A1
20150105851 Shalev et al. Apr 2015 A1
20150142096 Shalev May 2015 A1
20150196301 Bodewadt et al. Jul 2015 A1
20150202065 Shalev et al. Jul 2015 A1
20150351943 Shalev et al. Dec 2015 A1
20150374383 Bodewadt et al. Dec 2015 A1
20160030209 Shalev et al. Feb 2016 A1
20160157990 Shalev et al. Jun 2016 A1
20160193029 Shalev Jul 2016 A1
20160262880 Li et al. Sep 2016 A1
20160302950 Marmur et al. Oct 2016 A1
20170273809 Marmur et al. Sep 2017 A1
Foreign Referenced Citations (118)
Number Date Country
2 497 704 Mar 2004 CA
1194577 Sep 1998 CN
2453960 Oct 2001 CN
1748660 Mar 2006 CN
2817770 Sep 2006 CN
101045022 Oct 2007 CN
201058061 May 2008 CN
101980670 Feb 2011 CN
101998845 Mar 2011 CN
10213055 Sep 2002 DE
0893108 Jan 1999 EP
1 177 779 Feb 2002 EP
1 177 780 Feb 2002 EP
1 325 716 Jul 2003 EP
1470797 Oct 2004 EP
1759666 Mar 2007 EP
1961401 Aug 2008 EP
2266509 Dec 2010 EP
2298248 Mar 2011 EP
2702964 Mar 2014 EP
2000-279533 Oct 2000 JP
2002-253682 Sep 2002 JP
1996039104 Dec 1996 WO
9806355 Feb 1998 WO
1998027895 Jul 1998 WO
9913808 Mar 1999 WO
1999025273 May 1999 WO
9934748 Jul 1999 WO
1999051165 Oct 1999 WO
0028923 May 2000 WO
2000074595 Dec 2000 WO
2000076423 Dec 2000 WO
2002083038 Oct 2002 WO
2003034948 May 2003 WO
03099108 Dec 2003 WO
2004017868 Mar 2004 WO
2004045463 Jun 2004 WO
2004100836 Nov 2004 WO
05002466 Jan 2005 WO
2005034809 Apr 2005 WO
2005037138 Apr 2005 WO
2005041781 May 2005 WO
2005041783 May 2005 WO
2005046524 May 2005 WO
2005046526 May 2005 WO
2006007389 Jan 2006 WO
2006028925 Mar 2006 WO
2006036690 Apr 2006 WO
06070372 Jul 2006 WO
2006088905 Aug 2006 WO
2006130755 Dec 2006 WO
2007022495 Feb 2007 WO
2007039587 Apr 2007 WO
2007084547 Jul 2007 WO
2007115017 Oct 2007 WO
2007144782 Dec 2007 WO
08008291 Jan 2008 WO
2008021557 Feb 2008 WO
2008035337 Mar 2008 WO
2008042266 Apr 2008 WO
2008047092 Apr 2008 WO
2008047354 Apr 2008 WO
2008051704 May 2008 WO
2008053469 May 2008 WO
2008066923 Jun 2008 WO
2008107885 Sep 2008 WO
2008140796 Nov 2008 WO
2009078010 Jun 2009 WO
2009104000 Aug 2009 WO
2009116042 Sep 2009 WO
20091169041 Sep 2009 WO
09118733 Oct 2009 WO
2010024869 Mar 2010 WO
2010024879 Mar 2010 WO
2010027704 Mar 2010 WO
2010031060 Mar 2010 WO
2010042210 Apr 2010 WO
2010045238 Apr 2010 WO
2010062355 Jun 2010 WO
10088776 Aug 2010 WO
2010111583 Sep 2010 WO
2010128162 Nov 2010 WO
2010150208 Dec 2010 WO
2011004374 Jan 2011 WO
2011007354 Jan 2011 WO
2011055364 May 2011 WO
2011064782 Jun 2011 WO
2011067764 Jun 2011 WO
2011070576 Jun 2011 WO
2001052776 Jul 2011 WO
2011080738 Jul 2011 WO
2011095979 Aug 2011 WO
2011100290 Aug 2011 WO
2011106532 Sep 2011 WO
2011106533 Sep 2011 WO
2011106544 Sep 2011 WO
2011116307 Sep 2011 WO
2011136930 Nov 2011 WO
2012039748 Mar 2012 WO
2012049679 Apr 2012 WO
2012104842 Aug 2012 WO
2012111006 Aug 2012 WO
2012117395 Sep 2012 WO
2012176187 Dec 2012 WO
2013005207 Jan 2013 WO
2013030818 Mar 2013 WO
2013030819 Mar 2013 WO
2013065040 May 2013 WO
2013084235 Jun 2013 WO
2013171730 Nov 2013 WO
2014020609 Feb 2014 WO
2014108895 Jul 2014 WO
2014141232 Sep 2014 WO
2014188412 Nov 2014 WO
2016098113 Jun 2016 WO
2016113731 Jul 2016 WO
2016125137 Aug 2016 WO
2017081679 May 2017 WO
Non-Patent Literature Citations (194)
Entry
“E-vita® open plus” product brochure (JOTEC GmbH, Hechingen, Germany), 2010.
Fonseca A et al., “Intravascular ultrasound assessment of the novel AngioSculpt scoring balloon catheter for the treatment of complex coronary lesions,” J Invasive Cardiol 20(1):21-7 (Jan. 2008).
Khlif H et al., “Contribution to the Improvement of Textile Vascular Prostheses Crimping,” Trends in Applied Sciences Research 6(9):1019-1027 (2011).
An International Search Report dated Sep. 29, 2008, which issued during the prosecution of Applicant's PCT/IL08/000287.
A Written Opinion dated Sep. 29, 2008, which issued during the prosecution of Applicant's PCT/IL08/000287.
An International Search Report & Written Opinion both dated Nov. 26, 2013, which issued during the prosecution of Applicant's PCT/IL2013/050656.
An International Search Report dated Feb. 4, 2011, which issued during the prosecution of Applicant's PCT/IB2010/052861.
A Written Opinion dated Feb. 4, 2011, which issued during the prosecution of Applicant's PCT/IB2010/052861.
An International Search Report dated Dec. 3, 2010, which issued during the prosecution of Applicant's PCT/IL2010/000564.
A Written Opinion dated Dec. 3, 2010, which issued during the prosecution of Applicant's PCT/IL2010/000564.
An International Search Report dated Nov. 5, 2010, which issued during the prosecution of Applicant's PCT/IL2010/000549.
A Written Opinion dated Nov. 5, 2010, which issued during the prosecution of Applicant's PCT/IL2010/000549.
An International Search Report dated Aug. 4, 2011, which issued during the prosecution of Applicant's PCT/IL2010/000999.
An International Search Report dated Mar. 10, 2011, which issued during the prosecution of Applicant's PCT/IL2010/000917.
An International Search Report together with Written Opinion both dated Mar. 30, 2011, which issued during the prosecution of Applicant's PCT/IL2010/001018.
An International Search Report dated Apr. 18, 2011, which issued during the prosecution of Applicant's PCT/IL2010/001037.
An International Search Report dated May 23, 2011, which issued during the prosecution of Applicant's PCT/IL2010/001087.
An International Search Report dated Jun. 28, 2011, which issued during the prosecution of Applicant's PCT/IL2010/000135.
An International Search Report dated Jun. 30, 2009, which issued during the prosecution of Applicant's PCT/IL2008/001621.
A Written Opinion dated Jun. 30, 2009, which issued during the prosecution of Applicant's PCT/IL2008/001621.
An International Search Report dated Mar. 11, 2009, which issued during the prosecution of Applicant's PCT/IL2007/001312.
A Written Opinion dated Mar. 11, 2009, which issued during the prosecution of Applicant's PCT/IL2007/001312.
An English translation of an Office Action dated Aug. 25, 2011, which issued during the prosecution of Chinese Patent Application No. 200880014919.9.
An Office Action dated Nov. 12, 2010, which issued during the prosecution of U.S. Appl. No. 12/447,684.
An Office Action dated Apr. 27, 2011, which issued during the prosecution of U.S. Appl. No. 12/447,684.
An Office Action dated Feb. 25, 2013, which issued during the prosecution of U.S. Appl. No. 13/031,871.
An Office Action dated Feb. 27, 2013, which issued during the prosecution of U.S. Appl. No. 12/808,037.
An Extended European Search Report dated Jan. 2, 2013, which issued during the prosecution of Applicant's European App No. 08719912.1.
An International Search Report together with Written Opinion both dated Sep. 6, 2012, which issued during the prosecution of Applicant's PCT/IL2012/000190.
An International Search Report together with Written Opinion both dated Aug. 31, 2012, which issued during the prosecution of Applicant's PCT/IL2012/000148.
An Office Action dated Oct. 11, 2012, which issued during the prosecution of U.S. Appl. No. 13/031,871.
An Office Action dated Jun. 19, 2012, which issued during the prosecution of U.S. Appl. No. 12/808,037.
An International Search Report together with Written Opinion both dated Sep. 24, 2012, which issued during the prosecution of Applicant's PCT/IL2012/000060.
An International Search Report together with Written Opinion both dated Oct. 1, 2012, which issued during the prosecution of Applicant's PCT/IL2012/000241.
An International Search Report together with Written Opinion both dated Oct. 4, 2012, which issued during the prosecution of Applicant's PCT/IL2012/000269.
An International Search Report together with Written Opinion both dated Nov. 27, 2012, which issued during the prosecution of Applicant's PCT/IL2012/000300.
An Office Action dated Jul. 22, 2016, which issued during the prosecution of Chinese Patent Application No. 201480012648.9.
An Office Action dated Oct. 28, 2011, which issued during the prosecution of U.S. Appl. No. 12/529,936.
An Office Action dated Mar. 24, 2011, which issued during the prosecution of U.S. Appl. No. 12/529,936.
An International Search Report and a Written Opinion both dated Jun. 14, 2013, which issued during the prosecution of Applicant's PCT/IL2012/050506.
Van Prehn J. et al., “Oversizing of aortic stent grafts for abdominal aneurysm review: a systematic review of the benefits and risks,” Eur J Vase Endovase Surg. Jul. 2009;38(1):42-53. Epub May 9, 2009 (abstract only).
Fattori et al., Degenerative aneurysm of the descending aorta. Endovascular Treatment. pp. 1-11, 2007, European Association for Cardio-Thoracic Surgery.
An Office Action dated Jan. 12, 2016, which issued during the prosecution of U.S. Appl. No. 14/362,194.
European Search Report dated Aug. 31, 2016, which issued during the prosecution of Applicant's European App No. 14762507.3.
An Office Action dated Feb. 5, 2015, which issued during the prosecution of U.S. Appl. No. 13/384,075.
An Office Action dated Feb. 23, 2015, which issued during the prosecution of U.S. Appl. No. 13/513,397.
European Search Report dated Feb. 26, 2015, which issued during the prosecution of Applicant's European App No. 12806964.8.
An International Search Report and a Written Opinion both dated Mar. 18, 2015, which issued during the prosecution of Applicant's PCT/IL2014/050973.
An English translation of an Office Action dated Mar. 19, 2015, which issued during the prosecution of Chinese Patent Application No. 201080036970.7.
An English translation of an Office Action dated Oct. 8, 2014, which issued during the prosecution of Chinese Patent Application No. 201080036970.7.
European Search Report dated May 23, 2016, which issued during the prosecution of Applicant's European App No. 10832752.9.
An Office Action dated Mar. 26, 2015, which issued during the prosecution of U.S. Appl. No. 13/514,240.
European Search Report dated Mar. 20, 2015, which issued during the prosecution of Applicant's European App No. 08861980.4.
An International Search Report and a Written Opinion both dated Jun. 21, 2016, which issued during the prosecution of Applicant's PCT/IL2016/050014.
An Office Action dated Aug. 12, 2015, which issued during the prosecution of U.S. Appl. No. 13/513,397.
European Search Report dated Sep. 22, 2016, which issued during the prosecution of Applicant's European App No. 10834308.8.
An Office Action dated Aug. 3, 2016, which issued during the prosecution of U.S. Appl. No. 14/241,793.
An Office Action dated Sep. 22, 2016, which issued during the prosecution of Canadian Patent Application No. 2,782,513.
An Office Action dated Sep. 23, 2015, which issued during the prosecution of U.S. Appl. No. 13/384,075.
An Office Action dated Oct. 2, 2015, which issued during the prosecution of U.S. Appl. No. 13/577,161.
European Search Report dated Apr. 22, 2015, which issued during the prosecution of Applicant's European App No. 12828495.7.
An Office Action dated Apr. 14, 2015, which issued during the prosecution of U.S. Appl. No. 14/130,213.
European Search Report dated Jan. 18, 2016, which issued during the prosecution of Applicant's European App No. 10799521.9.
European Search Report dated Oct. 27, 2015 which issued during the prosecution of Applicant's European App No. 10835608.0.
An Office Action dated Feb. 23, 2016, which issued during the prosecution of U.S. Appl. No. 14/416,236.
An Office Action dated Mar. 7, 2016, which issued during the prosecution of U.S. Appl. No. 14/240,600.
An Office Action dated Feb. 1, 2016, which issued during the prosecution of U.S. Appl. No. 14/241,793.
An Office Action dated Feb. 19, 2016, which issued during the prosecution of U.S. Appl. No. 13/807,880.
An International Search Report and a Written Opinion both dated Feb. 17, 2016, which issued during the prosecution of Applicant's PCT/IL2015/051221.
European Search Report dated Mar. 11, 2016 which issued during the prosecution of Applicant's European App No. 11739497.3.
European Search Report dated Mar. 15. 2016 which issued during the prosecution of Applicant's European App No. 13825456.0.
An Office Action dated Mar. 28, 2016, which issued during the prosecution of U.S. Appl. No. 14/362,194.
An Invitation to pay additional fees dated Apr. 12, 2016, which issued during the prosecution of Applicant's PCT/IL2016/050014.
An International Search Report and a Written Opinion both dated Apr. 22, 2016, which issued during the prosecution of Applicant's PCT/IL2016/050049.
Scurr et al., “Fenestrated Aortic Stent Grafts,” Semin Intervent Radiol. Jun. 2007;24(2): 211-220.
European Search Report dated Oct. 27, 2016 which issued during the prosecution of Applicant's European App No. 14801036.6.
U.S. Appl. No. 61/265,793, filed Dec. 2, 2009.
Notice of Allowance dated Dec. 30, 2015, which issued during the prosecution of U.S. Appl. No. 14/130,213.
Notice of Allowance dated Oct. 16, 2015, which issued during the prosecution of U.S. Appl. No. 14/130,213.
Notice of Allowance dated Nov. 23. 2015, which issued during the prosecution of U.S. Appl. No. 14/130,213.
An Office Action dated Jan. 26, 2017, which issued during the prosecution of U.S. Appl. No. 14/572,156.
An Office Action dated Jul. 7, 2017, which issued during the prosecution of U.S. Appl. No. 14/572,156.
An Office Action dated Aug. 21, 2014, which issued during the prosecution of U.S. Appl. No. 13/384,075.
An Office Action dated Jun. 10, 2014, which issued during the prosecution of U.S. Appl. No. 13/505,996.
Notice of Allowance dated Nov. 10, 2016, which issued during the prosecution of U.S. Appl. No. 14/362,194.
An International Preliminary Report on Patentability dated Jun. 20, 2017, which issued during the prosecution of Applicant's PCT/IL2015/051221.
An Office Action dated Jul. 30, 2015, which issued during the prosecution of U.S. Appl. No. 14/240,600.
An Office Action dated May 28, 2015, which issued during the prosecution of U.S. Appl. No. 14/240,600.
An Office Action dated May 15, 2015, which issued during the prosecution of U.S. Appl. No. 13/577,161.
An Office Action dated Sep. 15, 2015, which issued during the prosecution of Canadian Patent Application No. 2,782,357.
An Office Action dated Mar. 28, 2014, which issued during the prosecution of U.S. Appl. No. 13/519,971.
U.S. Appl. No. 61/566,654, filed Dec. 4, 2011.
An International Search Report and a Written Opinion both dated Jul. 30, 2014, which issued during the prosecution of Applicant's PCT/IL2014/050174.
European Search Report dated Jun. 12, 2014, which issued during the prosecution of Applicant's European App No. 12855964.8.
European Office Action issued Dec. 17, 2014 in European Patent Application No. 12803376.8.
Supplementary European Search Report dated Feb. 24, 2014, which issued during the prosecution of Applicant's European App No. 12803376.8.
Invitation to Pay Additional Fees dated Jul. 30, 2014, which issued during the prosecution of Applicant's PCT/IL2014/050174.
Invitation to Pay Additional Fees dated May 13, 2014, which issued during the prosecution of Applicant's PCT/IL2014/050019.
Aortic Aneurysm O'Gara, Patrick T. Circulation. 2003; 107:e43-e45.
An Office Action dated Jan. 12, 2017, which issued during the prosecution of U.S. Appl. No. 14/518,542.
An Office Action dated Dec. 7, 2016, which issued during the prosecution of U.S. Appl. No. 14/400,699.
An Office Action dated Dec. 27, 2016, which issued during the prosecution of Chinese Patent Application No. 201510685240.4.
An International Search Report and a Written Opinion both dated Jan. 19, 2017, which issued during the prosecution of Applicant's PCT/IL2016/051207.
An Office Action dated Feb. 28, 2014, which issued during the prosecution of U.S. Appl. No. 13/512,778.
An International Preliminary Report on Patentability dated Jan. 7, 2014, which issued during the prosecution of Applicant's PCT/IL2012/000269.
An International Preliminary Report on Patentability dated Jan. 4, 2012, which issued during the prosecution of Applicant's PCT/IB2010/052861.
An International Preliminary Report on Patentability dated Dec. 23, 2013, which issued during the prosecution of Applicant's PCT/IL2012/000241.
An International Preliminary Report on Patentability dated Aug. 6, 2013, which issued during the prosecution of Applicant's PCT/IL2012/000060.
An English translation of an Office Action dated Nov. 28, 2013, which issued during the prosecution of Chinese Patent Application No. 200880126889.0.
An English translation of an Office Action dated May 16, 2014, which issued during the prosecution of Chinese Patent Application No. 200880126889.0.
An English translation of an Office Action dated Feb. 16, 2013, which issued during the prosecution of Chinese Patent Application No. 200880126889.0.
An English translation of an Office Action dated Jan. 28, 2014, which issued during the prosecution of Chinese Patent Application No. 201080036970.7.
An International Preliminary Report on Patentability dated Jan. 10, 2012, which issued during the prosecution of Applicant's PCT/IL2010/000549.
An International Preliminary Report on Patentability dated Jan. 17, 2012, which issued during the prosecution of Applicant's PCT/IL2010/000564.
An Office Action dated Jul. 28, 2014, which issued during the prosecution of U.S. Appl. No. 13/031,871.
An International Preliminary Report on Patentability dated Jun. 12, 2012, which issued during the prosecution of Applicant's PCT/IL2010/001037.
An International Preliminary Report on Patentability dated Mar. 4, 2014, which issued during the prosecution of Applicant's PCT/IL2012/000300.
An International Preliminary Report on Patentability dated May 6, 2014, which issued during the prosecution of Applicant's PCT/IL2012/050424.
An International Preliminary Report on Patentability dated May 8, 2012, which issued during the prosecution of Applicant's PCT/IL2010/000917.
An International Preliminary Report on Patentability dated Nov. 18, 2014, which issued during the prosecution of Applicant's PCT/IL2012/000190.
A Notice of Allowance dated Aug. 2, 2012, which issued during the prosecution of U.S. Appl. No. 12/529,936.
An International Preliminary Report on Patentability dated Jun. 5, 2012, which issued during the prosecution of Applicant's PCT/IL2010/000999.
An International Preliminary Report on Patentability dated Jun. 5, 2012, which issued during the prosecution of Applicant's PCT/IL2010/001018.
An International Preliminary Report on Patentability dated Jun. 10, 2014, which issued during the prosecution of Applicant's PCT/IL2012/050506.
A Notice of Allowance issued in U.S. Appl. No. 13/807,906 on Oct. 10, 2014.
A Restriction Requirement dated Jan. 29, 2014, which issued during the prosecution of U.S. Appl. No. 13/519,971.
An Advisory Action dated Feb. 13, 2014, which issued during the prosecution of U.S. Appl. No. 13/807,880.
An Office Action dated Jul. 24, 2014, which issued during the prosecution of Canadian Patent Application No. 2768228.
An International Search Report and a Written Opinion both dated Jul. 13, 2012, which issued during the prosecution of Applicant's PCT/IL2012/000083.
An International Search Report and a Written Opinion both dated Jul. 17, 2012, which issued during the prosecution of Applicant's PCT/IL2012/000095.
An Office Action dated Dec. 2, 2013, which issued during the prosecution of U.S. Appl. No. 13/807,880.
An International Search Report and a Written Opinion both dated Mar. 15, 2013, which issued during the prosecution of Applicant's PCT/IL2012/050424.
An Office Action dated May 20, 2013, which issued during the prosecution of U.S. Appl. No. 13/807,880.
Notice of Allowance dated Jun. 18, 2013, which issued during the prosecution of U.S. Appl. No. 13/523,296.
U.S. Appl. No. 61/505,132, filed Jul. 7, 2011.
An Office Action dated Apr. 10, 2014, which issued during the prosecution of Applicant's U.S. Appl. No. 13/807,906.
An Office Action dated Apr. 24, 2014, which issued during the prosecution of Applicant's U.S. Appl. No. 13/380,278.
An Office Action dated Apr. 28, 2014, which issued during the prosecution of Applicant's U.S. Appl. No. 13/939,798.
An Office Action dated Feb. 9, 2017, which issued during the prosecution of U.S. Appl. No. 14/772,016.
An Office Action dated Mar. 6, 2017, which issued during the prosecution of U.S. Appl. No. 13/979,551.
An Office Action dated Feb. 3, 2015, which issued during the prosecution of U.S. Appl. No. 12/447,684.
An International Preliminary Report on Patentability dated Feb. 3, 2015, which issued during the prosecution of Applicant's PCT/IL2013/050656.
A Notice of Allowance dated Jan. 7, 2014, which issued during the prosecution of U.S. Appl. No. 13/663,117.
European Search Report dated Oct. 31, 2014, which issued during the prosecution of Applicant's European App No. 12752054.2.
An Office Action dated Sep. 2, 2014, which issued during the prosecution of U.S. Appl. No. 12/447,684.
U.S. Appl. No. 61/448,199, filed Mar. 2, 2011.
An Office action dated Aug. 15, 2014, from the U.S. Patent and Trademark Office in counterpart U.S. Appl. No. 13/939,798.
U.S. Appl. No. 61/926,533, filed Jan. 13, 2014.
U.S. Appl. No. 61/528,242, filed Aug. 28, 2011.
U.S. Appl. No. 61/906,014, filed Nov. 19, 2013.
U.S. Appl. No. 61/775,964, filed Mar. 11, 2013.
U.S. Appl. No. 61/826,544, filed May 23, 2013.
U.S. Appl. No. 61/014,031, filed Dec. 15, 2007.
An Office Action dated Aug. 15, 2014, which issued during the prosecution of U.S. Appl. No. 13/512,778.
A Notice of Allowance dated Jan. 20, 2015, which issued during the prosecution of U.S. Appl. No. 13/383,128.
Notice of Allowance dated Nov. 7, 2014, which issued during the prosecution of U.S. Appl. No. 13/512,778.
International Preliminary Report on Patentability dated Aug. 21, 2013 in corresponding International Application No. PCT/IL2012/000083.
An Interview Summary dated Dec. 13, 2010, which issued during the prosecution of U.S. Appl. No. 12/447,684.
An Office Action dated Mar. 21, 2012, which issued during the prosecution of U.S. Appl. No. 12/808,037.
Notice of allowance dated May 22. 2013, which issued during the prosecution of U.S. Appl. No. 12/808,037.
U.S. Appl. No. 60/863,373, filed Oct. 29, 2006.
Notice of Allowance dated Dec. 19, 2014, which issued during the prosecution of U.S. Appl. No. 13/512,778.
An Office Action dated Sep. 11, 2015, which issued during the prosecution of U.S. Appl. No. 14/001,641.
An International Preliminary Report on Patentability dated Sep. 3, 2013, which issued during the prosecution of Applicant's PCT/IL2012/000095.
An International Search Report and a Written Opinion both dated Apr. 28, 2014, which issued during the prosecution of Applicant's PCT/IL2014/050019.
An Office action dated Sep. 4, 2014, from the U.S. Patent and Trademark Office in counterpart U.S. Appl. No. 13/519,971.
European Search Report dated Jun. 30, 2014, which issued during the prosecution of Applicant's European App No. 12741804.4.
Ryhanen J., in “Biocompatibility evaluation of nickel-titanium shape memory metal alloy,” Academic Dissertation, Faculty of Medicine, Department of Surgery, University of Oulu, Finland (May 1999).
Notice of allowance dated Jun. 24, 2014, which issued during the prosecution of Applicant's U.S. Appl. No. 13/380,278.
An International Search Report dated Nov. 28, 2014, which issued during the prosecution of Applicant's PCT/IL2014/050434.
An Interview Summary dated Feb. 28, 2012, which issued during the prosecution of U.S. Appl. No. 12/529,936.
An Office Action dated Nov. 3, 2014, which issued during the prosecution of Canadian Patent Application No. 2767596.
An Office Action dated Nov. 19, 2013, which issued during the prosecution of U.S. Appl. No. 13/663,117.
Office Action issued on Oct. 27, 2014 in Canadian Patent Application No. 2,785,953.
U.S. Appl. No. 61/678,182, filed Aug. 1, 2012.
U.S. Appl. No. 61/529,931, filed Sep. 1, 2011.
U.S. Appl. No. 61/553,209, filed Oct. 30, 2011.
U.S. Appl. No. 61/499,195, filed Jun. 21, 2011.
U.S. Appl. No. 61/749,965, filed Jan. 8, 2013.
Notice of Allowance dated August 5. 2019, which issued during the prosecution of U.S. Appl. No. 15/105,106.
U.S. Appl. No. 61/496,613, filed Jun. 14, 2011.
U.S. Appl. No. 61/221,074, filed Jun. 28, 2009.
U.S. Appl. No. 61/219,758, filed Jun. 23, 2009.
U.S. Appl. No. 61/264,861, filed Nov. 30, 2009.
An Interview Summary dated Sep. 25, 2014, which issued during the prosecution of U.S. Appl. No. 13/512,778.
An Interview Summary dated Apr. 24, 2014, which issued during the prosecution of U.S. Appl. No. 13/512,778.
An Office Action dated Jun. 18, 2013, which issued during the prosecution of U.S. Appl. No. 13/512,778.
Notice of Allowance dated Oct. 8, 2014, which issued during the prosecution of U.S. Appl. No. 13/512,778.
An Office Action dated Jan. 16, 2015, which issued during the prosecution of Chinese Patent Application No. 201080062714.5.
U.S. Appl. No. 62/093,497, filed Dec. 18, 2014.
An Office Action dated Jun. 29, 2018, which issued during the prosecution of U.S. Appl. No. 15/105,106.
An Office Action in Brazilian Appl. No. BR112017012425-4, dated Mar. 3, 2022, with English translation.
A Non-Final Office Action issued in U.S. Appl. No. 16/668,045, dated Mar. 3, 2022.
A Notice of Allowance issued in U.S. Appl. No. 16/668,045, dated Jun. 15, 2022.
Related Publications (1)
Number Date Country
20220346987 A1 Nov 2022 US
Provisional Applications (1)
Number Date Country
62093497 Dec 2014 US
Continuations (2)
Number Date Country
Parent 16668045 Oct 2019 US
Child 17863595 US
Parent 15105106 US
Child 16668045 US